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ABSTRACT 
 
A Pilot Fidelity Study of Listen-Empathize-Agree-Partner (LEAP) 
with Assertive Community Treatment (ACT) Mental Health Clinicians 
 
Mia A. Ihm 
 
The primary objective of this study was to examine clinicians’ fidelity to a 
promising new clinical intervention known as Listen-Empathize-Agree-Partner (LEAP) 
that addresses issues of poor insight, therapeutic alliance, and treatment adherence 
prevalent in the schizophrenia population.   A secondary purpose of this study was to 
assess the factor structure and psychometric properties of a measure developed to examine 
the core principles of the LEAP method.  Forty-eight mental health clinicians working in 
Assertive Community Treatment (ACT) programs randomized into intervention and 
control groups were assessed for fidelity to the LEAP method via the LEAP Fidelity 
Measure (LFM), a self-report instrument. Results revealed a three-factor structure of this 
measure which were labeled “Reflective Listening, Delaying and Opining,” “Partnering on 
Shared Goals,” and “Client-Centered Listening and Empathizing.”  Multivariate Analyses 
of Variance indicated that clinicians who were trained in LEAP had significantly higher 
levels of fidelity to the “Reflective Listening, Delaying and Opining” and “Partnering on 
Shared Goals” components than clinicians who were not trained in this method.  There 
were no significant differences between the groups on the “Client-Centered Listening and 
Empathizing” component.  Analyses did not reveal significant gender differences or effects 
based on years of general and specific ACT clinical experience between the two groups.  
However, in a post hoc analysis, a modest correlation between gender and fidelity to the 
“Client-Centered Listening and Empathizing” component showed that male clinicians 
tended to report higher fidelity to this specific set of interventions when compared to their 
female counterparts.  These results are discussed within the context of feasibility in 
training and implementing LEAP in real-world community mental health clinical settings.  
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Over the past decade, the Listen-Empathize-Agree-Partner (LEAP) program has 
been taught to tens of thousands of mental health practitioners worldwide to address the 
clinical challenges associated with limited insight, poor therapeutic alliance, and treatment 
non-adherence often observed in individuals diagnosed with schizophrenia (Amador, 
2012).  Despite the program’s popularity and high positive ratings from participants, no 
assessment of trainee fidelity to the program has ever been conducted.  The importance of 
establishing and maintaining fidelity to treatment protocols has been emphasized in the 
psychotherapeutic intervention literature for decades (Bellg, et al., 2004; Eysenck, 1952; 
Kernberg, 1976; Moncher & Prinz, 1991; Shapiro & Shapiro, 1983; VandenBos, 1980).  
However, similar to existing research on the LEAP program, few studies of clinical 
interventions have adequately addressed issues of treatment fidelity (for review, see 
Borrelli et al., 2005; Naleppa & Cagle, 2010).   
Schizophrenia is a severe and persistent mental illness that is associated with high 
personal, familial and societal costs (for review, see Harrison et al., 2001; Velligan, Lam, 
Ereshefsky, & Miller, 2003).  Despite evidence suggesting that poor insight into illness 
(Amador & Kronengold, 2004; McEvoy, 2004), limited therapeutic alliance (Frank & 
Gunderson, 1990; Prince, 2007; Tattan & Tarrier, 2000), and low treatment adherence  
(Davis et al., 2003; Svarstad, Shireman, & Sweeney, 2001; Velligan et al., 2003, 2008) 





research devoted to developing and evaluating specific psychotherapeutic interventions 
aimed at improving these aspects of the illness is alarming.  
LEAP (Amador, 2000, 2007, 2010) is a psychotherapeutic intervention comprised 
of communication strategies designed to strengthen the therapeutic alliance and improve 
treatment adherence by addressing problems of poor insight associated with this 
population. Research suggests that lack of insight into illness is highly prevalent among 
individuals diagnosed with schizophrenia (Amador & Paul-Odouard, 2000; Amador & 
Kronengold, 2004) with rates ranging from 29-59% (Cernovsky, Landmark, Merskey, & 
Husni, 2004; Freudenreich, Deckersbach, & Goff, 2004; Larøi et al., 2000).  Regarding 
treatment outcomes, acknowledging and addressing issues of poor insight is critical in this 
population as lack of awareness into illness has been found to be among the best predictors 
of treatment non-adherence among individuals with schizophrenia (Amador & 
Kronengold, 2004).  
Poor insight has also been found to be significantly related to low therapeutic 
alliance in this population (Misdrahi, Petit, Blanc, Bayle, & Llorca, 2012; Wittorf et al., 
2009).  Research suggests that individuals with poor awareness into their illness have 
difficulty engaging in a positive therapeutic relationship (Johnson, Penn, Bauer, Meyer, & 
Evans, 2007).  This finding is particularly alarming as research has consistently indicated 
that the relationship between patient and therapist is primarily responsible for change in the 
process of therapeutic treatment (Henry, Strupp, Schacht, & Gaston, 1994; Martin et al., 
2000; Safran, Goldfried, & Muran, 1995).  Consequently, low therapeutic alliance has been 
found to be associated with treatment non-adherence (for review, see Velligan, Lam, 





diagnosed with schizophrenia (Horvath & Luborsky, 1993; Horvath, 1994; Martin et al., 
2000). 
Due to the poor adherence to treatment demonstrated in the schizophrenia 
population, another goal of LEAP is to improve treatment adherence. The literature on 
adherence rates suggests that up to 60% of individuals diagnosed with schizophrenia are 
non-adherent to prescribed medications (Dolder, Lacro, Leckband, & Jeste, 2003; Gilmer 
et al., 2004; Velligan et al., 2003) and research also reveals high rates of disengagement 
from psychotherapeutic and psychosocial interventions in this population (Drake, 2009; 
Marshall & Lockwood, 2010; Marshall, Lockwood, & Green 2010).   Taken together, non-
adherence and intermittent adherence to treatment is associated with symptom relapse, re-
hospitalization, and high cost of treatment among individuals with schizophrenia (Davis et 
al., 2003; Velligan et al., 2003, 2008; Weiden et al., 1995).  
As schizophrenia poses specific challenges to treatment and prognosis due to the 
poor insight, low therapeutic alliance, and treatment non-adherence associated with this 
diagnosis, psychotherapeutic approaches, such as LEAP, that aim to address these 
particular areas of the illness should be examined.  LEAP incorporates components of 
motivational enhancement, cognitive-behavioral and client-centered therapies and provides 
communication tools that serve as an adjunctive intervention to other forms of psycho-
therapy and psychosocial education (Amador, 2000, 2007, 2010, 2012).  The primary goal 
of LEAP is to develop a trusting and accepting environment that enables the practitioner to 
become more persuasive in his or her treatment recommendations to the patient.  LEAP 





Community Treatment (ACT), that serve individuals at high risk for repeated psychiatric 
crises, treatment non-adherence and service disengagement.   
ACT is an evidence-based treatment framework that supports patients with Severe 
and Persistent Mental Illness (SPMI), such as schizophrenia, by providing intensive 
outpatient treatment ‘in vivo’ in their community of choice, including the patient’s home, 
local mental health clinic, or hospital setting (Marshall & Lockwood, 2010).  The program 
facilitates psychiatric recovery and stability, as well as increased daily functioning and 
quality of life across various contexts (e.g., home, school, work, community) and 
relationships (e.g., peers, family). Due to the serious costs of chronic mental illness, the 
importance of using evidence-based approaches to improve patient outcomes is further 
underscored.   
The extant research on issues of treatment fidelity conclude that not only do fidelity 
studies promote important methodological benefits to psychotherapy research, enhanced 
clinician fidelity to treatment protocols is critical for the successful evaluation of research-
based clinical interventions as it is otherwise impossible to examine the effectiveness of a 
given treatment or to make valid comparisons between treatments (Borrelli et al., 2002, 
2005; Mowbray, Holter, Teague, & Bybee, 2003).  Despite the emerging focus on 
establishing empirically-supported treatments in psychotherapy research, the literature 
indicates that few studies adequately address clinician fidelity to treatments (Borrelli et al., 
2002; Naleppa & Cagle, 2010). As such, researchers argue that establishing treatment 
fidelity is necessary to the development and dissemination of innovative, credible, and 
clinically-applicable interventions and programs for chronically mentally ill individuals 





Based on this literature, addressing issues of insight deficits, low therapeutic 
alliance, and limited treatment adherence among individuals diagnosed with schizophrenia 
is a clinical problem that needs to be addressed.  As such, LEAP, comprised of 
psychotherapeutic techniques developed to specifically address these clinical challenges, 
will be presented as a promising adjunctive intervention that is the focus of this study.  
Based on the research arguing that fidelity assessments are critical in evaluating the 
effectiveness of clinical interventions, the primary purpose of this investigation is to assess 
clinicians’ fidelity to communication strategies that represent core components of LEAP.  
Clinician gender, years of general clinical experience, and years of specific clinical 
experience within the ACT program are evaluated as potential moderator variables.  A 
secondary purpose of this study is to examine the factor structure of a measure developed 
to assess core principles of LEAP in an attempt to identify and compare differences 
between groups based on the principal components of this intervention.   
 
Review of the Literature 
 
 In this chapter, the research literature related to insight into illness, therapeutic 
alliance, and treatment adherence associated with schizophrenia will be reviewed.  
Promising research on a clinical intervention known as LEAP will be presented as a 
psychotherapeutic approach that specifically addresses poor insight, low therapeutic 
alliance, and treatment non-adherence in this population.  The applicability of LEAP 
principles to the ACT program, a treatment approach that has been empirically-validated as 





discussed.   Furthermore, the literature arguing the importance of fidelity assessments to 
the effective development and dissemination of clinical interventions will be reviewed.  
The rationale and scientific value of the present study will be discussed in light of this 
literature.  
 
Insight Into Illness 
 The current edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV-TR; American Psychiatric Association, 2000) cites scientific consensus that lack 
of insight into mental illness is a prevalent feature of schizophrenia and is a manifestation 
of the illness itself, rather than a coping strategy.  At the time of its publication, the DSM-
IV-TR revision chairpersons and experts reviewed approximately two hundred empirical 
studies (personal communication, Xavier Amador, co-chair of DSM-IV-TR Schizophrenia 
and Related Disorders section).  In the decade prior to the publication of the last edition of 
the DSM, the extant literature on insight in this disorder had increased about twenty-fold. 
This was due, in large part, to increased agreement on terminology and phenomenology 
making comparison between studies and replications possible. For example, Amador, 
Strauss, Yale, and Gorman (1991) proposed a comprehensive and multidimensional 
definition of insight, stating that insight encompasses current and retrospective awareness 
of: (1) having a mental disorder, (2) the effects of medication, (3) the psychosocial 
consequences of mental disorder, and (4) the specific signs and symptoms associated with 
a given mental disorder.  The authors further distinguish between unawareness of illness, 
which reflects a failure to acknowledge the presence of specific deficits, signs, or 





the expressed belief that a specific deficit, sign, or symptom of illness does not stem from 
mental dysfunction, as distinct dimensions of insight.   Research suggests that insight into 
illness can be modality-specific rather than global, meaning that one can be aware of some 
aspects of their illness while lacking insight into others (Amador et al., 1994; Rosen, 
Mukherjee, Olarte, Varia, & Cardenas, 1982; Tremeau et al., 1997).   
Research indicates that unawareness of illness is prevalent in a large proportion of 
people with schizophrenia (Amador & Paul-Odouard, 2000; Amador & Kronengold, 
2004).  The International Pilot Study of Schizophrenia (1973), a multi-national study 
conducted by the World Health Organization, found that 81% of 811 patients denied that 
they had a mental illness.  A second international study involving more chronically-ill 
patients with schizophrenia (Wilson, Ban, & Guy, 1986) reported that 89% of 768 patients 
denied they had an illness.  In both studies, insight was defined as present if there was 
“some awareness of mental illness” and absent if “mental illness was vigorously denied.”  
More recent literature has also documented high rates of insight deficits in patients 
with schizophrenia.  In a comprehensive study assessing insight into illness among patients 
with schizophrenia, schizoaffective disorder, and mood disorders with psychosis, Amador 
et al. (1994) found that 57.4% of patients with schizophrenia (n = 221) exhibited moderate 
to severe unawareness of having a mental disorder, 31.5% had severe unawareness of the 
social consequences of mental disorder, and 21.7% had severe unawareness of the efficacy 
of medication.  The authors reported a range of 27.8% to 57.6% on unawareness of specific 
signs and symptoms associated with mental illness.  Similarly, Sevy, Nathanson, 
Visweswaraiah, and Amador (2004) reported that among 96 patients diagnosed with 





treatment response, 41.8% lacked awareness for social consequences, and 58.2% lacked 
awareness for symptoms.  Other researchers found rates of unawareness of mental illness 
ranging from 29% to 59% in schizophrenia samples (Cernovsky, Landmark, Merskey, & 
Husni, 2004; Freudenreich, Deckersbach, & Goff, 2004; Larøi et al., 2000; Young, Davila, 
& Scher, 1993). 
Research investigating varying levels of illness unawareness among psychotic 
patients has yielded significant results.  In a study of insight involving 87 outpatients 
diagnosed with schizophrenia (n = 54) and schizoaffective disorder (n = 33), Dickerson, 
Boronow, Ringel, and Parente (1997) found that 49.5% of patients were at least 
moderately impaired, while 25% of patients had severe deficits in illness awareness.  In a 
study of early-onset schizophrenia (n = 264), schizoaffective (n = 40), and 
schizophreniform (n = 231) disorder patients, Keshavan, Rabinowitz, DeSmedt, Harvey, 
and Schooler (2004) reported rates of 12% with no impairment, 12.4% with minimal 
impairment, 20.9% with mild impairment, 31.4% with moderate impairment, 13.7% with 
moderate to severe impairment, 9.4% with severe impairment, and 0.6% with extreme 
impairment in awareness of illness.  Thus, these researchers found that 76% of these 
patients exhibited mild to severe levels of insight deficits regarding their mental illness.  
Furthermore, in a study of first-episode schizophrenia (n = 30) and schizoaffective disorder 
(n = 5) inpatients, Shad, Muddasani, Prasad, Sweeney, and Keshavan (2004) found that 
prior to pharmacological treatment, 51.4% had good insight, 17.1% had partial insight, and 
31.4% had poor insight. 
Although patients diagnosed with other psychiatric disorders, such as 





lack of insight into mental illness, research suggests that self-awareness deficits appear to 
be more severe and pervasive in those diagnosed with schizophrenia (Amador et al., 1994; 
Pini, Cassano, Dell’Osso, & Amador, 2001).  Moreover, Carpenter, Bartko, Carpenter, and 
Strauss (1976) not only found poor insight to be a prevalent symptom of schizophrenia but 
also reported that it was a significant discriminating factor between schizophrenia and 
other psychotic disorders.  There is also evidence suggesting that schizophrenic individuals 
with the deficit syndrome, characterized by primary enduring negative symptoms (i.e., 
affective flattening, alogia, or avolition), exhibit significantly lower levels of insight 
compared to non-deficit schizophrenia patients (Amador et al., 1994; Ratakonda, Gorman, 
Yale, & Amador, 1998). 
 In the psychoanalytic literature, deficits of insight into mental illness have been 
studied historically using subjective interpretation of case studies concluding that poor 
insight results from unconscious psychological defenses or conscious coping strategies 
(e.g. Levy, McGlashan, & Carpenter, 1975; Semrad, 1966; Van Putten, Crumptom, & 
Yale, 1976).  Although few studies have investigated the direct relationship between 
defensiveness and insight in schizophrenia (Kasapis, 1996; Nelson, 1997), there have been 
consistent findings characterizing lack of insight into illness as a prevalent symptom of 
schizophrenia resulting from organic brain dysfunctions rather than psychological 
processes (APA, 2000; Prigatano & Schachter, 1991; Amador & David, 2004).  Many have 
argued that insight deficit in schizophrenia bears a strong resemblance to anosognosia 
related to neurological disorders such as stroke and other brain disorders (APA, 2000).  
When patients with schizophrenia and associated poor insight are compared to those with 





characteristics, including gross lack of awareness of illness persisting despite evidence to 
the contrary, confabulations to explain behaviors or observations that contradict their belief 
of not being ill, and a compulsion to prove this belief (Amador & Paul-Odouard, 2000; 
Flashman, 2004).  Additionally, there is growing evidence linking lower levels of insight 
to neuropsychological dysfunctions, particularly in frontal lobe functioning (Larøi et al., 
2000; Morgan & David, 2004; Shad et al., 2004; Young et al., 1993).  Thus, research 
establishing associations between deficits in insight, enduring negative symptoms (deficit 
syndrome), and particular neuropsychological deficits have informed neuro-cognitive 
conceptualizations of illness unawareness in schizophrenia.  
 Importantly, deficits in insight into illness have been reported to significantly 
influence treatment outcomes in schizophrenia (Amador & Kronengold, 2004; McEvoy, 
2004).  Poor insight has been found to be among the best predictors of non-adherence and 
partial adherence to medications (Amador & Kronengold, 2004), with acknowledgement of 
illness (Bartko, Herczeg, & Zador, 1988; Kemp & David, 1996; Smith et al., 1999; Weiden 
et al., 1991) and advantages of medications (Buchanan, 1992; McEvoy, Appelbaum, 
Apperson, Geller, & Freter, 1989; McEvoy et al., 1993) being significantly related to 
treatment adherence and avoidance of re-hospitalization. Furthermore, research indicates 
that poor insight into illness is also associated with low therapeutic alliance in this 
population (Kemp & David; 1996; Misdrahi, Petit, Blanc, Bayle, & Llorca, 2012; Wittorf 
et al., 2009).  For example, Johnson and colleagues (2007) found that level of insight 
predicted quality of therapeutic alliance among individuals with schizophrenia, suggesting 







 Researchers and practitioners of psychotherapy have asserted that the therapeutic 
alliance – broadly defined as an open, trusting, and collaborative relationship between a 
patient and clinician – is an essential component of the therapeutic process of change.  The 
concept of the alliance originated in early psychoanalytic theories (e.g., Freud, 1912; 1913) 
and was expanded by Carl Rogers’ Client-Centered Therapy (Farber, 2007; Rogers, 1957; 
Rogers & Wood, 1974). Although differences exist in conceptualizations of the therapeutic 
alliance, most theoretical definitions include three common themes: (1) the collaborative 
nature of the relationship, (2) affective attachment between patient and therapist, and (3) 
mutually agreed-upon objectives for treatment (Bordin, 1979; Gaston, 1990; Horvath & 
Symonds, 1991).  
 Within a historical context, Freud (1912; 1913) theorized that a positive therapeutic 
attachment creates an environment of safety and trust allowing the patient an opportunity 
to reflect on past experiences and to associate the analyst with significant figures from the 
past.  Although a positive attachment is an important aspect of analysis, it is not viewed as 
a “real” relationship between the analyst and patient as the attachment is based on the 
patient’s projections of qualities defining past relationships onto the analyst, a process 
understood as transference.  As such, the primary task in psychoanalysis is to derive 
interpretations regarding the various forms of transference that arise within the therapeutic 
relationship.  Within this theoretical framework, the alliance is not viewed as an agent of 
therapeutic change in and of itself. 
  In 1951, the publication of Carl Rogers’ book, Client-centered Therapy, not only 





suggested that the therapeutic relationship in itself may serve a healing function.  To create 
a therapeutic environment that facilitates change, Rogers emphasized the use of a non-
directive style of listening and empathy that promotes affective regulation.  Through the 
use of empathy, the therapist responds to the client in a nurturing and accepting manner 
that enables the client to modulate their affective experiences and to internalize the 
therapist’s validating stance (Fosha, 2001; Watson, 2007).  This process is facilitated 
through the therapist’s communication of warmth and caring as well as affective 
authenticity and genuineness, what Rogers (1951, 1957) called unconditional positive 
regard and congruence, respectively.   
Rogers proposed three hypotheses regarding the therapeutic conditions that 
facilitate change (1951, 1957).  First, he suggested that empathy, congruence and 
unconditional positive regard, viewed as the therapist’s contributions to developing a 
therapeutic alliance, are “necessary and sufficient conditions” of therapeutic change 
(Rogers, 1957, p. 87).  Rogers made the theoretical argument, for the first time, that the 
relationship that the therapist provides the patient, rather than techniques applied within 
this context, is the agent of therapeutic change. Second, Rogers argued that these 
conditions supplied by the therapist are responsible for change regardless of the therapist’s 
theoretical orientation.  Again, this hypothesis underscored the importance of the 
therapeutic relationship and also implied that the therapist’s most valuable contribution to 
the process of therapy is interpersonal rather than technical.  Third, Rogers suggested that 
the client-centered approach was distinctive as the therapist was responsible for providing 
these transformational relationship conditions.  The implication of this hypothesis is that 





on the therapist’s ability to create an environment that allows the patient to access and 
enhance his or her growth potential.   
 Unique to his time, Carl Rogers insisted upon empirical validation of his theoretical 
hypotheses and to identify the essential aspects that facilitate change in therapy (Farber, 
2007; Horvath, 2000; Watson, 2007).  Results of numerous studies on his original theories 
are generally supportive of his contention that a positive therapeutic alliance is associated 
with favorable patient outcomes (for review, see Horvath & Symonds, 1991).  However, 
contrary to Rogers’ assertion, research suggests that the patient’s perception of empathy, 
congruence and unconditional positive regard in the therapeutic relationship was more 
predictive of outcome rather than objective measurements of these conditions (Farber & 
Lane, 2002; Mitchell, Bozart, & Krauft, 1977).   
 In his presidential address to the Annual Conference of the Society for 
Psychotherapy Research in 1975, Edward Bordin presented a reformulation of the concept 
of the therapeutic alliance (Bordin, 1976).  He altered the psychodynamic framework by 
suggesting that the alliance was primarily a conscious relationship in the present rather 
than predominantly informed by unresolved past relationships.  He supported Rogers’ 
(1951, 1957) claim that the therapeutic alliance was fundamental to all helping processes.  
However, in contrast to Rogers’ contention that the therapist was the sole provider of the 
“necessary and sufficient conditions” of change, Bordin’s concept of the alliance entailed 
agreements and collaboration between the therapist and the patient.  Bordin’s (1976, 1994) 
conceptualization of the alliance incorporates three associated components: (1) Bonds, 
referring to interpersonal attachments (i.e., liking, trusting, etc.), (2) Tasks, defined as 





focus of therapy, and (3) Goals, involving consensus regarding the short- and long-term 
expectations between the therapist and patient.  Bordin’s reformulation of the client-
centered approach redirected attention onto the therapeutic alliance. This attention also 
generated extensive research investigating the relationship between the alliance and 
treatment outcomes.   
The therapeutic alliance has become central to contemporary conceptualizations of 
the therapeutic process primarily due to the consistent finding that the quality of the 
therapeutic alliance is related to subsequent therapeutic outcomes (for review, see Horvath 
& Symonds, 1991).  Researchers have investigated the effectiveness of psychotherapy 
across theoretical orientation that has yielded consistent evidence that psychotherapies are 
generally effective independent of the therapist’s theoretical perspective (Lambert & 
Bergin, 1994; Martin, Garske, & Davis, 2000).  Many researchers consider the therapeutic 
alliance to be a common factor across therapy modalities accounting for positive treatment 
outcomes (Henry, Strupp, Schacht, & Gaston, 1994; Martin et al., 2000; Safran, Goldfried, 
& Muran, 1995), and Farber (2007) has evaluated the enduring and pervasive contributions 
of the client-centered approach to the field of psychotherapy.    
 The quality of the therapeutic alliance has also been consistently associated with 
treatment outcomes in individuals diagnosed with schizophrenia (Horvath & Luborsky, 
1993; Horvath, 1994; Martin et al., 2000).  A stronger therapeutic alliance has been 
associated with reduced symptom severity and higher community functioning (Neale & 
Rosenheck, 1995; Olfson, Glick, & Mechanic, 1993), higher medication and treatment 
adherence (Frank & Gunderson, 1990; Corriss et al., 1999; Olfson et al., 2000), increased 





Delaney, 1995), and higher global patient functioning (Neale & Rosenheck, 1995; 
Svensson & Hansson, 1999a).  Moreover, the absence of a positive alliance with a therapist 
predicted worse patient outcomes, including increased symptom severity and lower overall 
quality of life (Tattan & Tarrier, 2000). Furthermore, negative symptoms associated with 
schizophrenia, including blunted affect, emotional withdrawal, and a detached 
interpersonal style, have been found to significantly predict poorer alliance in psychotic 
(Couture et al., 2006) and non-psychotic samples (Hersoug, Monsen, Havik, & Hogeland, 
2002; Kivlighan, 1998; Saunders, 2001).  In a comprehensive study of predictors of 
treatment outcomes in schizophrenia, Frank and Gunderson (1990) found that patients with 
schizophrenia who developed a strong therapeutic alliance with a therapist within the first 
6 months of treatment evidenced significantly lower treatment drop-out rates even when 
multiple pretreatment characteristics, including social and vocational functioning and 
severity of cognitive disorganization, were controlled for.  Patients in this study who 
reported low alliance ratings showed a treatment drop-out rate of 72%.   
 Although the impact of lack of insight into illness and quality of therapeutic 
alliance on treatment outcomes in individuals with schizophrenia have been established 
independently, the influence of insight on the therapeutic alliance has rarely been studied 
(Wittorf et al., 2009).  Kemp and David (1996) asserted that poor insight into illness is 
associated with decreased participation in treatment, suggesting that patients with poor 
insight may experience difficulty engaging in a therapeutic alliance.  Johnson, Penn, Bauer, 
Meyer, & Evans (2007) supported this assertion when they found that higher baseline 
levels of insight predicted stronger group alliance at the mid-point of group therapy among 





Despite emerging evidence suggesting that insight into illness affects the quality of 
the therapeutic alliance, few studies to date have investigated the impact of both insight 
and alliance on treatment outcomes in individuals with schizophrenia (Prince, 2007).  One 
study (Prince, 2007) found an inverse relationship between awareness of illness and 
therapeutic alliance in relation to the number of inpatient hospitalizations among patients 
with schizophrenia.  These results suggest that a higher number of hospitalizations was 
significantly related to increased levels of insight and decreased therapeutic engagement 
and alliance in a schizophrenic sample.  Furthermore, Chadwick (2001) found that 
although therapeutic alliance and insight into illness significantly influenced medication 
adherence in patients with schizophrenia, no significant interaction effects were found.   
In sum, research indicates that poor insight into illness and low therapeutic alliance 
are generally associated with poor treatment outcomes among individuals diagnosed with 
schizophrenia.  As such, the specific contributions of these aspects of illness to treatment 
adherence, or non-adherence, should be evaluated.   
 
Treatment Adherence 
 The primary form of treatment for schizophrenia is pharmacological intervention 
that targets symptoms associated with the illness and reduces relapse rates (Ayuso-
Gutiérrez & del Rio Vega, 1997; Davis, Chen, & Glick, 2003). Despite the benefits 
afforded by neuroleptic medications, poor adherence to medications is a limitation 
common in the treatment of schizophrenia (Fenton, Blyler, & Heinssen, 1997; Hogarty & 
Ulrich, 1998).  Medication adherence relates to “the extent to which the patient’s behavior 





Although researchers have often used the term “non-compliance” to describe patient’s low 
follow-up rates to pharmacological treatment, Velligan and colleagues (2006) recommend 
changing our terms to “non-adherence” or “non-concordance” to promote the notion that 
medical treatment is a collaborative enterprise between patient and physician. 
 Medication non-adherence is one of the strongest predictors of relapse and re-
hospitalization in schizophrenia.  Research suggests that up to 60% of individuals 
diagnosed with schizophrenia are non-adherent to prescribed medications (Dolder, Lacro, 
Leckband, & Jeste, 2003; Fenton, Blyler & Heinssen, 1997; Gilmer et al., 2004; Sullivan, 
Wells, Morgenstern, & Leake, 1995; Velligan, Lam, Ereshefsky, & Miller, 2003; Weiden 
et al., 1995). In a summary of studies on medication adherence rates, McEvoy (2004) 
reported that approximately 50% of patients with schizophrenia take medications as 
prescribed with little or no supervision, 35% of patients adhere to medications if 
supervised, and 15% of patients avoid taking medications under any circumstance.  Poor 
adherence to medications has been associated with re-hospitalization, impediments to 
treatment progress, and high cost of treatment among individuals with schizophrenia 
(Davis et al., 2003; Svarstad, Shireman, & Sweeney, 2001; Velligan et al., 2003, 2008; 
Weiden et al., 1995).  
Furthermore, several researchers have reported that schizophrenia patients who 
receive intermittent treatment at the onset of symptoms have less favorable outcomes 
compared to those who receive long-term and consistent treatment (Ayuso-Gutiérrez & del 
RioVega, 1997; Carpenter et al., 1990; Herz et al., 1991; Schooler et al., 1997).  Weiden 
and Glazer (1997) found that among 64 “revolving door” patients (patients with frequent 





hospitalizations.  In one study (Wyatt et al., 1995), inconsistent adherence to medications 
was associated with a two-fold increase in the number of inpatient admissions and a four-
fold increase in total duration of hospitalization.  Thus, at a monthly relapse rate of 3.5% 
for patients with good adherence to oral antipsychotic medications versus 11% for those 
with poor adherence, approximately 40% of good adherence patients would relapse within 
one year compared to nearly 100% for poor adherence patients (Csernansky & Schuchart, 
2002).  It should be noted that even if non- or partial-adherence does not result in 
hospitalization, poor adherence to treatment can compromise symptom control and 
undermine overall adjustment among individuals with schizophrenia (Masand & 
Narasimhan, 2006).  Despite recent advances in pharmacological treatments, second-
generation antipsychotic medications with increased efficacy and improved side effect 
profiles have not substantially improved rates of medication adherence in schizophrenia 
(Dolder et al., 2003; Velligan et al., 2003).   
 Some researchers have suggested that perhaps the persistent and pervasive nature 
of schizophrenia contributes to partial or complete non-adherence to medications.  The 
negative symptoms associated with schizophrenia have been found to reduce motivation 
and drive (Schmand et al., 1994), and cognitive deficits adversely affecting attention and 
memory make it difficult to adhere to medication regimens (Sharma & Antonova, 2003).  
Treatment-related factors, including the delayed onset of the therapeutic effects of most 
psychiatric medications (Oehl, Hummer, & Fleischhacker, 2000), complicated medication 
regimens (Greenberg, 1984; Oehl et al., 2000), and the therapeutic alliance with the 
physician (Frank & Gunderson, 1990; Corriss et al., 1999; Olfson et al., 2000) have been 





factors have been established, including supervision (Parkes, Brown & Monck, 1982), 
family supportiveness (Buchanan, 1992; Young, Zonana, & Shepler, 1986), high expressed 
emotion in the family (Oehl et al., 2000; Tamminga & Schulz, 1991), and family attitude 
toward psychiatric treatment (Oehl et al. 2000).  Velligan and colleagues (2006) have 
asserted that although adherence rates are poor across a variety of medical and mental 
illnesses, the consequences of medication non-adherence in schizophrenia can be 
devastating due to the high personal, familial and societal costs associated with the 
disorder. 
 Although pharmacological treatment is an essential aspect of treatment for 
schizophrenia, little evidence suggests that antipsychotic medication alone significantly 
improves global functioning (Amminger et al., 1999; Baum & Walker, 1995; Halford & 
Hayes, 1995; Macdonald, Jackson, Hayes, Baglioni, & Madden, 1998). Although 
pharmacotherapy is effective in the treatment of acute symptoms of schizophrenia, 
medications alone do little to alleviate residual cognitive and social deficits associated with 
the disorder (Mueser, Bellack, Douglas, & Morrison, 1991).  There is growing evidence 
that optimal treatment for schizophrenia also encompasses psychological strategies 
(Altamura et al., 2000; Amminger et al., 1999; Tarrier et al., 1993).   
 Although psychotherapeutic interventions are varied, most approaches geared 
toward individuals with psychosis include goals such as reducing the disability and distress 
associated with residual symptoms, reducing emotional concerns, and promoting an 
understanding of the illness to decrease rates of relapse (Penn et al., 2004).  Researchers 
have investigated the impact of engagement in psychotherapy with treatment outcomes in 





improved symptom control, quality of life, maintenance in the community, and 
psychosocial integration (Altamura et al., 2000; Amminger et al., 1999; Kuipers et al., 
1998). A number of studies have suggested that psychological interventions can be 
effective in reducing the intensity of psychotic symptoms, such as hallucinations and 
delusions, among patients with schizophrenia (Dickerson, 2000; Gould, Mueser, Bolton, 
Mays, & Goff, 2001; Tarrier et al., 1999; Sensky et al., 2000). In a study involving acutely 
psychotic patients, Drury, Birchwood and Cochrane (2000) found that cognitive behavior 
therapy adjunctive to antipsychotic medication resulted in a significantly faster and more 
complete recovery from the psychotic episode.  Thus, research suggests that 
psychotherapeutic interventions are important adjunctive strategies that can improve 
outcomes for patients diagnosed with schizophrenia.  
Tarrier and colleagues (1993) purport that due to the pervasive nature of 
schizophrenia, a treatment approach involving pharmacological and psychological 
interventions is necessary to improve the patient’s level of functioning and quality of life.  
Furthermore, as the majority of patients with schizophrenia require long-term treatment 
due to the chronic nature of the illness, greater stability can be achieved through 
comprehensive intervention strategies focusing on psychoeducation, support, and the 
patient’s view of the illness to promote and enhance treatment progress (Altamura et al., 
2000; Tarrier et al., 1993).   
Despite the serious outcomes associated with medication non-adherence in 
schizophrenia, the paucity of research devoted to devising and evaluating specific 
interventions aimed at improving treatment adherence is surprising. The use of 





examined.  Psychoeducation is a widely used intervention focused primarily on increasing 
patient’s knowledge regarding schizophrenia, encompassing information about symptoms, 
treatment and medications, with the goal of increasing understanding and promoting 
adherence.  Several studies have evaluated the effectiveness of individual and group 
psychoeducational interventions in increasing medication adherence, however, there is 
little evidence to suggest that psychoeducation alone is an effective means of increasing 
adherence to medication (Atkinson, Coia, Gilmour, & Harper, 1996; Gray, 2000; Smith, 
Birchwood, & Haddrell, 1992).  In a randomized controlled trial of 44 patients with 
schizophrenia taking clozapine, Gray (2000) found that although three sessions of 
structured individual patient education improved patients’ understanding of their treatment, 
there was no effect on enhancing adherence to medications.  Two independent meta-
analyses (Dolder et al., 2003; Zygmunt, Olfson, Boyer, & Mechanic, 2002) concluded that 
psychoeducational interventions were the least successful at improving medication 
adherence in schizophrenia.  Thus, the literature on psychoeducation suggests that while 
educational interventions may improve patients’ understanding of pharmacological 
treatment, this understanding does not improve adherence to medications.  However, both 
meta-analyses also concluded that interventions incorporating aspects of cognitive and 
motivational enhancement therapies were the most promising in addressing treatment non-
adherence in schizophrenia.   
 Given the strong association between treatment adherence and outcomes for 
individuals with schizophrenia, cognitive therapies incorporating motivational 
interviewing (MI) have been evaluated as therapeutic interventions that may affect 





including substance abuse (Baker et al., 2002; Barrowclough et al., 2001; Graeber, 
Moyers, Griffith, Guajardo, & Tonigan, 2003), goal identification (Corrigan, McCracken, 
& Holmes, 2001), and insight and treatment adherence (Rüsch & Corrigan, 2002), in 
addition to medication adherence among individuals with schizophrenia (Kemp, Hayward, 
Applewhaite, Everitt, & David, 1996; Kemp, Kirov, Hayward, Everitt, & David, 1998; 
O’Donnell et al., 2003).  Originally based in substance abuse research, MI is an 
intervention that uses Prochaska and colleagues’ (Prochaska, DiClemente, & Norcross, 
1992) stages to address issues of motivation for change collaboratively with the patient. 
This model of change is conceptualized as a step-wise phenomenon in which individuals 
proceed through distinct stages (i.e. precontemplation, contemplation, preparation, action, 
maintenance, and relapse) to achieve meaningful behavior change (Arkowitz & Miller, 
2008).  MI emphasizes the importance of motivation as a contextual factor rather than a 
personality trait, and reduces the role of confrontation when addressing resistance to 
change (Miller & Rollnick, 1991). In this model, effective change occurs when an 
intervention matches the patient’s particular stage of change rather than a “one-size-fits-
all” approach.  Thus, failure to pursue aftercare treatment is not viewed as a sign of 
resistance or character pathology, but rather as representative of an effort to change at an 
earlier stage (Swanson, Pantalon, & Cohen, 1999).  Furthermore, collaboration is an 
important aspect of MI as the therapist and patient focus solely on goals that are mutually 
agreed upon and are often generated by the patient. MI encourages patients to weigh the 
risks and benefits of change, uses an empathic response to the exploration of ambivalence 
regarding illness and treatment, and promotes the patient’s self-efficacy regarding change 





goals, explore obstacles to treatment and make commitments to change (Miller & Rollnick, 
1991). 
When using MI to address medication adherence, the four basic principles (express 
empathy, develop discrepancy, roll with resistance, and support self-efficacy; Miller & 
Rollnick, 2002) create an atmosphere of acceptance and attentive listening, which is 
conducive to a collaborative relationship.  The accepting relationship provides a context in 
which the patient can voice and explore his or her ambivalence toward treatment and 
medications.  Within the frame of MI, the therapist does not attempt to persuade the patient 
to accept a diagnosis, rather, the patient is encouraged to contemplate how particular 
behaviors (such as not taking medications) might help achieve or interfere with their self-
identified goals (McCracken & Corrigan, 2008).  Rüsch and Corrigan (2002) suggest that 
this approach helps patients overcome any cognitive deficits associated with their illness 
by focusing on concrete problems and personal goals rather than abstract concepts.  
Furthermore, by accepting ambivalence as a part of change, rather than a form of 
resistance, patients’ self-efficacy can be bolstered through the decision-making process.     
There have been few controlled randomized studies that specifically evaluate the 
effectiveness of MI in improving adherence to pharmacological treatment in schizophrenia.  
Kemp and colleagues (Kemp et al., 1996, 1998) used the principles of MI to develop what 
they call ‘Compliance Therapy.’ Unlike broader based cognitive therapies that focus 
primarily on patient’s affect and symptom status, compliance therapy was developed as a 
short-term intervention with the primary goal of improving medication adherence 
following hospital discharge (Kemp et al., 1996). As in other cognitive therapy 





psychiatric history is reviewed. In the next phase, the patient’s ambivalence toward 
treatment is explored.  This phase is followed by a focus on medications as a useful 
strategy in improving the patient’s quality of life.   
In Kemp and colleagues’ (1996) study, the compliance therapy intervention (n = 
39) consisted of four to six 20- to 60-minute sessions conducted twice weekly.  The control 
group (n = 35) received supportive counseling for a similar number and duration of 
sessions.  The authors found that individuals who received compliance therapy had 
significantly higher medication adherence rates than those who were in the control group. 
They also reported that the compliance therapy group achieved significant secondary 
outcomes, including improved insight, better attitudes toward treatment and longer time to 
inpatient admission. Furthermore, these differences were maintained at 3-, 6-, and 18-
month follow-up intervals.  However, in a similar study, O’Donnell and colleagues (2003) 
were unable to replicate the findings that Kemp et al. reported. The authors reported that 
the power of the study may have been insufficient to detect a difference between the two 
experimental groups.   
In another clinical trial, Gray and colleagues (Gray et al., 2006) conducted a single-
blind, multi-center, randomized controlled trial of the effectiveness of compliance therapy 
on 409 outpatient and inpatient individuals with schizophrenia.  Participants in the 
compliance therapy group received eight weekly sessions lasting an average of 30-50 
minutes.  The control group received the same number of sessions addressing didactic 
health education specifically excluding any compliance therapy skills or techniques.  The 
authors reported no significant difference between the intervention and control groups at 





adherent participants also yielded non-significant results in relation to medication 
adherence.  Gray et al. suggest that sample selection bias may account for the non-
significant results as a large proportion of patients initially referred to the trial were 
excluded from the study. It should be noted that analyses on participant attrition indicate 
that the individuals who dropped out of the trial tended to have histories of longer inpatient 
hospitalizations (p = .022) than those who completed the trial. As such, the authors suggest 
that their sample may have been biased towards a subsample of more cooperative and 
treatment-adherent participants who were unlikely to benefit significantly from compliance 
therapy.  Based on the inconsistent results of these studies, it is unclear whether the 
evidence suggests that compliance therapy effectively improves medication adherence in 
schizophrenia. 
 Based on the research literature that indicates that poor insight into illness, low 
therapeutic alliance, and treatment non-adherence are factors contributing to poor 
outcomes in individuals diagnosed with schizophrenia, therapeutic interventions, such as 
LEAP, should be explored as promising approaches that address specific clinical issues 
associated with this population.   
 
Listen-Empathize-Agree-Partner 
Listen-Empathize-Agree-Partner (LEAP; Amador, 2000, 2007, 2010; Paillot, 
Goetz, & Amador, 2009) is an intervention comprised of communication strategies 
designed to strengthen therapeutic alliance with the ultimate aim of improving treatment 
adherence.  Based on Medication Adherence and Insight Therapy (MAIT; Amador & 





patient-centered therapy approaches and provides communication tools that serve as an 
adjunctive intervention to support therapeutic goals.   
In his review of the empirical status of Carl Rogers’ “necessary and sufficient 
conditions” (empathy, congruence and unconditional positive regard) for therapeutic 
change and the enduring contributions of the client-centered approach to the field of 
psychotherapy, Farber (2007) suggests that although difficult to define and measure, 
empathy may be the most central feature of the client-centered approach.  Furthermore, 
Bohart and colleagues (Bohart, Elliott, Greenberg, & Watson, 2002) suggest that empathy 
may lead to positive outcomes by increasing patient satisfaction in therapy which, in turn, 
increases patients’ adherence to therapists’ interventions and treatment recommendations.  
They also suggest that empathy may provide a corrective emotional experience and allows 
the patient to feel respected and understood within the context of therapy.  Lastly, these 
authors propose that empathy influences outcomes by promoting patients’ exploration of 
feelings, facilitating emotional reprocessing, and mobilizing efforts to change.  Aligned 
with the client-centered approach, LEAP acknowledges the importance of empathy, 
genuineness, and positive regard, as well as the influence of the therapeutic alliance on 
patient outcomes. 
Core characteristics of LEAP include reflective listening, respect for the patient’s 
perspective and choices, reality testing only at the patient’s request, and an empathic 
stance. In LEAP, practitioners listen carefully to the patient’s point of view and accurately 
reflect their understanding without commenting, disagreeing or arguing.  This approach is 
focused on reducing the patient’s resistance to talking about their illness and to help the 





and expectations.  To further enhance the patient’s experience of being heard and 
understood, the practitioner empathizes with the experiences that the patient shares.  LEAP 
places particular emphasis on empathizing with any feelings that are associated with the 
patient’s delusions without commenting on the content of the delusions.  This approach 
aims to validate the feelings elicited by the delusions, and thereby validating the patient’s 
experiences, without reality testing.  Also, LEAP aims to achieve collaboration through 
establishing mutually agreed-upon goals between the practitioner and patient.  Special 
emphasis is placed on acknowledging the personal choices of the patient and respecting 
that the patient is responsible for the decisions they make in life. When discussing choices, 
it is important for the practitioner to maintain a neutral stance by helping the patient 
consider the positive and negative consequences of their decisions. Through this process, 
the patient and practitioner partner in fulfilling the mutual goals. The ultimate goal of 
LEAP is to develop a trusting and accepting environment that enables the clinician or 
practitioner to become more persuasive in his or her treatment recommendations to the 
patient (Amador, 2007).  
The effectiveness of LEAP in enhancing treatment adherence in schizophrenia has 
been examined in a single-blind, randomized controlled trial by Paillot, Goetz and Amador 
(2009).  In their study, 54 pre-discharge inpatients receiving long-acting injectable 
antipsychotic medications (either typical or atypical) were assigned to either the 
experimental or control group.  Those in the experimental group received 14 weeks of 
LEAP, consisting of weekly sessions lasting approximately one hour.  The control group 
received a similar number of sessions of client-centered supportive psychotherapy. The 





to medications than the control group.  Furthermore, they reported significant secondary 
outcomes for the LEAP group, including improvements in motivation to take medication, 
insight into the achieved effects of medication, attitudes toward treatment, and insight 
regarding their illness. Although the authors state that additional studies of LEAP as a 
clinical intervention are necessary, the results of their study suggest that LEAP appears to 
be a promising intervention aimed at improving medication adherence in schizophrenia. 
 Based on extant literature, the Schizophrenia Patient Outcomes Research Team 
(PORT; Dixon et al., 2010) concluded that “there is insufficient evidence to recommend 
any specific intervention to promote adherence to antipsychotic medications among 
persons with schizophrenia” (p. 61). Furthermore, commenting on the scant literature on 
clinical interventions that specifically target medication non-adherence in schizophrenia, 
Nosé, Barbui, Gray, and Tansella (2003) concluded that “experimental studies have to 
address the effectiveness of educational strategies, psychotherapeutic programs and 
specific service policies in large samples of patients recruited in many different settings 
and followed in the long term” (p. 204) and that patients with schizophrenia should be 
considered separate from those with other psychiatric diagnoses.  However, Zygmunt and 
colleagues (2002) concluded that among existing interventions that target medication non-
adherence in schizophrenia, interventions based on principles of motivational interviewing 
and models of community care such as Assertive Community Treatment are the most 








Assertive Community Treatment 
 Given the significant personal, familial and societal costs associated with chronic 
mental illness and schizophrenia, in particular, the importance of identifying and 
examining treatment modalities and contexts that improve patient outcomes is emphasized.  
The 2010 Cochrane Review (Marshall & Lockwood, 2010; Marshall, Lockwood & Green, 
2010) concluded that Assertive Community Treatment (ACT) is an effective evidence-
based treatment framework for individuals with severe mental illness for treatment non-
adherence or for repeated psychiatric crises requiring a range of clinical, rehabilitation, and 
social services.  Evidence-based practices are defined as “interventions for which there is 
consistent scientific evidence showing that they improve patient outcomes” (Drake et al., 
2001, p. 179). Despite the extensive evidence for efficacious and effective mental health 
interventions, research suggests that the majority of individuals with severe mental illness 
do not routinely receive such interventions (Drake et al., 2001; Leff, Thornicroft, Coxhead, 
& Crawford, 1994).  Due to the serious personal, familial, and societal costs of severe 
mental illness, the importance of using evidence-based approaches to improve patient 
outcomes is further emphasized.   
ACT is a widely-used, intense and comprehensive mental health program model 
that serves patients with severe mental illness who do not readily benefit from clinic-based 
services, but who are at high risk for psychiatric hospitalization (Bond, Drake, Mueser, & 
Latimer, 2001).   ACT was developed in the 1970s by Stein and Test (1980) as a 
community alternative to psychiatric hospitalization.  In the ACT model, a multi-





severe mental illness.  ACT uses a holistic approach toward treatment that encompasses 
treatment, housing, finances, and other factors that impact patients’ quality of life.   
 Although ACT has been modified since it was initially developed, there is 
widespread agreement among researchers on most of the critical ingredients of the model 
(McGrew & Bond, 1995).  ACT is composed of a group of mental health professionals 
representing various disciplines, including psychiatrists, psychologists, social workers, 
nurses, rehabilitation counselors, and substance abuse counselors.    Although the overall 
social service system is fragmented, often requiring patients to navigate various agencies 
and programs to receive necessary treatment, ACT possesses the structure and the 
resources to address issues related to treatment, rehabilitation, substance use, practical 
assistance, social services, and family services tailored to the needs of the patient.  ACT 
clinicians meet daily to discuss issues related to patient care, including treatment plans, 
rehabilitation efforts, and problem solving.  The supportive organizational structure of the 
ACT program has also been shown to reduce burn-out among team members when 
compared to standard case management programs (Boyer & Bond, 1999).  In addition, low 
patient-staff ratios are an essential component of the ACT program that ensures adequate 
individualization of services for patients, particularly as the literature suggests that 
caseloads that are too large results in ineffective case management services (Björkman & 
Hansson, 2000; King, Le Bas & Spooner, 2000).  Although the 10:1 ratio has been 
frequently used a benchmark, ACT also takes into consideration caseload characteristics 
that may alter the ratio (Bond et al., 2001).   
ACT programs aim to strengthen patients’ abilities to adapt well in the community 





the majority of their contacts with patients and others involved in their treatment in home 
and community settings, rather than in clinics or offices.  Stein and Test hypothesized that 
in vivo interactions with patients would be a more accurate means to assess patient 
functioning and a more natural way to teach effective skills. Home visits also facilitate 
rapid access to services, including delivery of medications and crisis intervention. 
Furthermore, ACT clinicians utilize home visits as a means of ‘assertive outreach’ in 
continued efforts towards engagement of reluctant or uncooperative patients (Marshall & 
Lockwood, 2010; Marshall, Lockwood, & Green 2010).  Increasing and maintaining 
medication adherence is a major priority of the ACT program.  ACT clinicians emphasize 
the importance of accurate assessment regarding diagnosis and symptom reduction, choice 
of medications incorporating appropriate dosages and duration of treatment, and 
management of adverse side effects in accordance with evidence-based practice guidelines 
(Buchanan et al., 2010).  In addition to treatment management, ACT clinicians focus on a 
wide range of issues related to everyday living, including housing, finances, and shopping, 
specifically targeting problem areas for patients.  Incorporating all of these elements, ACT 
can be summarized as an intensive model of care providing treatment, rehabilitation and 
case management for individuals with severe and persistent mental illness (Bond et al., 
2001).  
Although ACT is often misunderstood as a type of case management, there are two 
key differences between these treatment approaches (Marshall & Lockwood, 2010; 
Marshall, Lockwood, & Green 2010).  First, ACT emphasizes teamwork and team 
responsibility in regards to patient care (Essock & Kontos, 1995). In other words, ACT 





case management model emphasizes professional autonomy and individual responsibility 
in patient care.  Second, ACT adheres to a specified model of treatment (see above) 
whereas case management is guided by general theoretical concepts (Ellison et al., 1995).  
There is general consensus that not all patients with severe mental illness require 
the intense level of care that ACT programs provide.  Currently, most ACT programs 
target a subset of individuals in this population who do not respond well to less-intensive 
treatment modalities and are frequent users of emergency psychiatric services (Bond et al., 
2001).  Admission criteria for ACT teams typically include frequent prior psychiatric 
inpatient hospitalizations or long-term hospitalizations, co-occurring substance use 
disorders, homelessness, as well as involvement in the legal system (Bond & Salyers, 
2004).  
ACT has been extensively researched as a comprehensive treatment model for 
individuals with severe mental illness.  Results of randomized controlled trials of ACT 
have most consistently found that ACT programs contribute to lower rates of psychiatric 
hospitalizations and homelessness compared to standard care (Bustillo, Lauriello, Horan & 
Keith, 2001; Coldwell & Bender, 2007; Marshall & Lockwood, 2010; Marshall, 
Lockwood, & Green 2010; Morse et al., 2006; Nelson, Aubry & Lafrance, 2007).  Other 
controlled studies have documented significant differences between ACT programs 
relative to standard care in reduced duration of inpatient hospitalization (Burns & Santos, 
1995; Bush, Langford, Rosen & Gott, 1990; Dekker et al., 2002; Essock & Kontos, 1995; 
Lehman, Dixon, Kernan, DeForge, & Postrado, 1997; Marshall & Lockwood, 2010; 
Marshall, Lockwood, & Green 2010; Rosenheck & Neale, 1998; Stein & Test, 1980; 





(Lehman, Dixon, Kernan, DeForge, & Postrado, 1997; Lehman et al.,1999; Scott & Dixon, 
1995; Morse Calsyn, Allen, Tempelhoff, & Smith, 1992; Sytema, Wunderink, Bloemers, 
Roorda, & Wiersma, 2007), decreased symptomatology (Stein & Test, 1980; Morse et al., 
1997; Wolff et al., 1997; Hamernik & Pakenham, 1999; Fekete et al., 1998), longer 
duration in stable community housing (Nelson et al., 2007; Essock & Kontos, 1995; Morse 
et al., 2006; Stein & Test, 1980; Ziguras & Stuart, 2000), greater rates of employment 
(Marshall & Lockwood, 2010; Marshall, Lockwood, & Green 2010), and greater patient 
and family satisfaction with services (Burns & Santos, 1995; Ziguras & Stuart, 2000; 
Marshall & Lockwood, 2010; Marshall, Lockwood, & Green 2010; Morse et al., 1992; 
1997).  Notably, ACT interventions appear to be most effective in populations with high 
rates of hospitalization (Burns et al., 2007).   
Furthermore, based on Marshall and Lockwood’s (2010a) extensive Cochrane 
Review meta-analysis, severely and persistently mentally ill (SPMI) individuals enrolled in 
ACT versus standard community care and hospital-based rehabilitation programs were 
more likely to maintain contact with clinicians, were less likely to have psychiatric hospital 
admissions, and spent less time in hospitals.  The review also found that ACT was superior 
to standard care in regards to housing, employment, and patient satisfaction. These results 
are particularly interesting as there was no difference in mental status or social functioning 
between the ACT and community care individuals.   
There is evidence that ACT programs significantly improve medication adherence 
among SPMI individuals (Stein & Test, 1980; Bush et al., 1990; Ford et al., 1995; Sands & 
Cnaan, 1994).   In a randomized controlled study of the effectiveness of ACT, Stein and 





either the ACT intervention group or to standard care.  The authors reported significantly 
higher rates of medication adherence in the ACT group as well as lower rates of 
hospitalization. In another randomized controlled study of ACT, Bush and colleagues 
(1990) assigned 28 patients (86% with schizophrenia) to either the ACT intervention group 
or to standard case management.  The authors reported that patients in the ACT group had 
significantly higher rates of medication adherence as well as general adherence to their 
treatment plans.  Furthermore, results also showed that individuals in the ACT group had 
lower rates of hospitalization and shorter duration of inpatient stays.   In addition, in Sands 
and Cnann’s (1994) randomized controlled study of ACT versus intensive case 
management, the authors found that patients assigned to the ACT group had significantly 
higher rates of medication adherence.   
As a result of extensive research evaluating ACT programs in improving outcomes 
for SPMI patients, ACT has been widely recognized as an evidence-based treatment 
framework (Bond & Salyers, 2004; Dixon et al., 2010; Drake et al., 2001; Marshall & 
Lockwood, 2010; Marshall, Lockwood, & Green 2010; Phillips et al., 2001).  The 
dissemination of ACT as an effective treatment approach for the SPMI population has been 
supported by governmental reports (Surgeon General, 2000), expert consensus panels 
(Dixon et al., 2010), and advocacy groups such as the National Alliance for the Mentally 
Ill (NAMI; Allness & Knoedler, 2003).   Based on this literature and the patient population 
served by ACT, interventions that address issues related to poor insight into illness, low 
therapeutic alliance, and treatment non-adherence, such as LEAP, should be examined.  
Furthermore, the extent to which clinicians working within this framework are able to 





Fidelity Studies of Psychological Interventions 
 Demonstrating the efficacy and effectiveness of clinical interventions is a critical 
component of psychological research.  As such, intervention research encompassing 
outcome studies, clinical trials and feasibility studies are essential in establishing 
scientifically-validated, practice-based approaches.  Fidelity to treatment, also known as 
treatment integrity, refers to the extent to which a clinical intervention was implemented as 
intended (Vermilyea, Barlow, & O’Brien, 1984; Yeaton & Sechrest, 1981). Establishing 
treatment fidelity requires accurate description, measurement, and implementation of the 
mechanism of change of a given clinical intervention.  Verification of fidelity confirms that 
the manipulation of the independent variable occurred as planned, allowing for accurate 
and appropriate interpretation of results (Czajkowski, 2011; Bellg et al., 2004; Hogue et 
al., 2008; Naleppa & Cagle, 2010; Perepletchikova & Kazdin, 2005).  Without this 
confirmation, it is impossible to draw accurate conclusions regarding treatment effects as 
significant results could be due to unknown active components added to the intervention, 
inactive components omitted from the intervention, or to an effective intervention 
(Moncher & Prinz, 1991).  The overall goal in enhancing treatment fidelity is to “increase 
scientific confidence that changes in the dependent variable are attributable to the 
independent variable” (Borrelli et al., 2005; p. 852).  
Emerging research suggests that fidelity studies promote important methodological, 
statistical and practical benefits, and strong fidelity is critical for successful dissemination 
of research-based clinical interventions.  First and foremost, when studies adequately 
monitor and control for the consistent implementation of an intervention, outcomes can be 





internal validity (Calsyn, 2000; Hohmann & Shear, 2002; Naleppa & Cagle, 2010).  
Establishing treatment fidelity also improves a study’s construct validity (Farrington, 
2003), content validity (Calsyn, 2000), and enhances statistical power and external validity 
by minimizing random and unintended variability in data (Bellg et al., 2004; Crits-
Christoph & Mintz, 1991).  Thus, verification of fidelity in clinical intervention research is 
necessary to maintain internal and external validity, to make fair comparisons between 
replicable treatments, and to draw accurate conclusions regarding treatment efficacy.  
Bellg and colleagues (2004) also suggest that verification of fidelity can have significant 
implications in successful dissemination of research focusing on conceptualization, 
comparison and application of efficacious clinical interventions.   
Despite the demand for accountability in the discipline of psychotherapy and the 
associated increase in clinical intervention research over the past several decades, much of 
this research has neglected issues of treatment fidelity.  Early intervention research was 
generally remiss in differentiating between treatment conditions, provided only vague 
descriptions of treatment conditions, and often presented insufficient information to 
compare or replicate treatment methods. Following Eysenck’s (1952) challenge regarding 
the effectiveness of psychotherapy and the rise of the community mental health movement 
of the early 1960s, concern for treatment fidelity in research and practice increased 
(Moncher & Prinz, 1991).  Rogers’ Client-Centered Therapy (Rogers & Dymond, 1954) 
was among the first clinical interventions to be examined systematically.  Increased 
emphasis on gathering in-session data occurred in the 1970s to promote adherence to 
treatment protocols, differentiation of treatment conditions and control of extraneous 





fidelity and lead to the proliferation of treatment manuals, Moncher and Prinz (1991) state 
that the methodological problems associated with the failure to demonstrate treatment 
fidelity has “plagued” the study of psychotherapy (p. 249).  Bellg and colleagues (2004) 
also purport that despite the importance of methodological procedures promoting treatment 
fidelity in research, these strategies “are not emphasized in research-training curricula, and 
their relative lack of perceived importance is also evidenced by the scant reporting of 
treatment fidelity practices in journal articles” (p. 443).  
 Meta-analyses of clinical intervention research suggest that the majority of existing 
studies have failed to adequately address issues of treatment fidelity.  Moncher and Prinz 
(1991) evaluated 359 treatment outcome studies conducted from 1980 – 1988 to determine 
the degree to which investigators considered treatment fidelity in research articles 
published in clinical psychology, behavior therapy, psychiatry, and marital and family 
therapy journals. Their evaluation focused on (1) the training of the researchers, (2) the 
procedures used to encourage fidelity, (3) the aspects of treatment that were confirmed, (4) 
the methods of assessing fidelity, and (5) the utilization of fidelity measures in interpreting 
results. Moncher and Prinz reported that although greater consideration of adherence to 
treatment and promotion of fidelity occurred over the decade, the majority (55%) of the 
studies included in the meta-analysis failed to address issues related to treatment fidelity.  
The authors also noted that there were no significant differences across journal domains in 
addressing the various aspects of fidelity.  Borrelli et al.’s (2005) meta-analysis of 342 
studies published in major health behavior change journals from 1990 – 2000 yielded 
similar results.  Their evaluation focused on aspects of treatment fidelity encompassing 





categories.  The utilization of treatment fidelity strategies varied greatly across categories, 
ranging from 63 – 94% for study design, 16 – 25% for training, 6 – 46% for delivery, 40 – 
53% for receipt, and 46 – 69% for enactment.  Although the authors hypothesized 
increased utilization of strategies aiming to promote treatment fidelity over time, they 
reported similar results to Moncher and Prinz’s meta-analysis and found a non-significant 
trend, indicating a decrease in the use of strategies over time.  Interestingly, they also noted 
that the lowest percentage of strategy use was found in the training category.  The authors 
of both meta-analyses emphasized the importance of addressing issues pertaining to 
treatment fidelity in future research and proposed guidelines for the enhancement of 
treatment fidelity. 
 Mowbray and colleagues (2003) state that the “use of valid fidelity criteria is now 
an expected component of quality evaluation practice” (p. 316). Guidelines for assessing 
and enhancing treatment fidelity were described by the Treatment Fidelity Workgroup as 
part of the National Institutes of Health (NIH) Behavioral Change Consortium (BCC).  The 
purpose of the BCC was to provide the necessary infrastructure to support collaboration 
between numerous NIH-funded health behavior change projects.  It is important to note 
that preservation of treatment fidelity was imperative in these projects as they involved 
theory testing within real-world settings.  As such, the BCC developed a comprehensive 
treatment fidelity framework relevant for health behavior change research and clinical 
practice with specific guidelines and recommendations for best practices across the 
categories of Design, Training, Delivery, Receipt, and Enactment (Bellg et al., 2004; 
Borrelli et al., 2002; 2005).  The Design category describes factors that should be 





for study replication.  The BCC recommends providing information on provider 
background (i.e. credentials, experience) and articulating the theoretical framework on 
which the clinical intervention is based.  It is also recommended that researchers establish 
strategies to monitor and decrease the potential for contamination between the treatment 
and control conditions, and to specify the dose and intensity of the intervention.  The 
Training category consists of important considerations when using human providers in 
intervention research.  The BCC encourages consideration of specific competencies 
required for successful implementation of the intervention and recruiting providers who are 
not only capable of implementing the intervention but who also adhere to its theoretical 
foundation.  Careful consideration and reporting of training methods, standardization of 
training, measurement of provider skill acquisition, and maintenance of skills is also 
recommended.  The Delivery category focused on processes that monitor and improve 
delivery to verify that the intervention was implemented as intended.  Strategies to 
improve fidelity in this category include examining whether the content and dose of the 
intervention delivery was as conceptualized and assessing provider adherence to various 
aspects of the intervention plan.    
For outcome research, the BCC also provides recommendations for Receipt and 
Enactment.  Treatment Receipt focuses on ensuring that participants understand the 
information provided in the intervention by assessing for literacy, education, and language 
proficiency and by assessing the participant’s ability to utilize the skills taught in the 
intervention.  Treatment Enactment consists of processes to monitor and improve the 
participant’s ability to incorporate the intervention skills in their daily lives.  The BCC 





one category can compromise the internal validity of the overall study despite adherence in 
other fidelity categories (Bellg et al., 2004; Borrelli et al., 2002; 2005). 
 In summary, although the importance of establishing fidelity to treatments has been 
underscored in the literature for decades and recent research on clinical interventions has 
emphasized the development and dissemination of empirically-supported interventions, 
past and current research suggest that few studies of psychotherapeutic approaches address 
issues of treatment fidelity. As such, addressing this discrepancy in clinical intervention 
research is necessary.   
 
Purpose of Study 
 
Given the findings regarding the high personal, familial and societal costs 
associated with schizophrenia and the extant literature on negative outcomes related to 
poor insight into illness, limited therapeutic alliance, and low treatment adherence in this 
population, the importance of examining clinical interventions, such as LEAP, that aim to 
improve these aspects of the illness is underscored.  It can be argued that the organizational 
structure and treatment philosophy of the ACT program are particularly suited for LEAP 
interventions as they primarily serve chronically mentally ill individuals who have 
demonstrated the severity of their illness through histories of multiple psychiatric 
hospitalizations as well as chronic service disengagement and treatment non-adherence.  
Any clinical intervention, such as LEAP, is only as effective as the level of adherence 
demonstrated by the practitioner who claims to utilize it. For this reason and given the 





development and dissemination of effective clinical interventions, as well as the dearth of 
research addressing intervention fidelity, the present study examines how closely trained 
mental health clinicians claim to adhere to the LEAP method.  To understand those aspects 
of the intervention that are more or less easily learned and implemented, it is imperative to 
attempt identifying the principal components or the “active ingredients” that encompass 
the LEAP method and differentiate it from other treatment modalities.   For that reason, the 
present study evaluates the psychometric properties of a new measure assessing core 
components of LEAP. 
The overall goal of this study, in light of the literature on schizophrenia and clinical 
intervention research, is to explore the feasibility of training and implementing the LEAP 
method, an intervention designed specifically to address issues of insight, therapeutic 
alliance, and treatment adherence in the schizophrenia population, particularly within the 
context of the ACT community mental health practice setting.   The specific aims of this 
study are (a) to examine the factor structure of the LEAP Fidelity Measure to identify the 
core components of the LEAP method and (b) to assess and compare ratings of the LEAP 
Fidelity Measure components between ACT program mental health clinicians who were 
assessed prior to and following LEAP training.  Furthermore, as research evaluating 
therapist variables that contribute to differences in patient outcomes has been inconclusive, 
clinician gender, as well as years of general and ACT-specific clinical experience will be 
evaluated as potential moderator variables.  By adding to the research literature concerning 
the feasibility of training clinicians on new interventions that are widely used, the present 
study will contribute to the development of innovative, credible, and clinically-applicable 





Hypotheses and Analysis Plan 
 
This study examines LEAP principal components derived from the LEAP Fidelity 
Measure and potential differences in component ratings between ACT clinicians who were 
assessed pre- and post-LEAP training.  The contribution of therapists to client outcomes in 
therapy have been the focus of research, particularly within the context of establishing 
empirically-supported psychological interventions (for review, see Kazdin, 1997; Beutler, 
Machado & Neufeldt, 1994).   
Research has evaluated specific therapist variables contributing to differences in 
outcomes, with specific focus on demographic characteristics (i.e., age, gender, race, 
religion), training characteristics (i.e., degree, training, years of experience), theoretical 
orientation, and personality characteristics.  Studies examining the effects of therapist 
gender (Beutler et al., 1994) on treatment outcomes have yielded inconclusive results. In 
Bowman’s (1993) review of the literature, he concludes that the research presents three 
competing hypotheses regarding the effect of therapist gender on client outcomes: (a) 
female therapist are more effective than their male counterparts (e.g., Bowman, Scogin, 
Floyd, & McKendree-Smith, 2001; Fisher, 1989), (b) gender matching between client and 
therapist produce better outcomes (e.g., Luborksy, Auerbach, Chandler, Cohen, & 
Bachrach, 1971; Persons, Persons, & Newmark, 1974); and (c) therapist gender is not 
significantly associated with outcomes (e.g., Huppert et al., 2001; Sexton & Whiston, 
1991; Zlotnick, Elkin, & Shea, 1998; Vocisano et al., 2004).  Research has also evaluated 
the effect of amount of therapist clinical experience on treatment outcomes, and overall, 





of the therapist (Beutler et al., 1994).  Some studies report that greater therapist experience 
is associated with better client outcomes, although the differences appear to be modest 
(Crits-Christoph et al., 1991; Huppert et al., 2001; Stein & Lambert, 1995). Furthermore, 
the literature evaluating the relationship between therapist degree and treatment outcomes 
reflect mixed conclusions.  For example, the only meta-analysis on this variable (Smith, 
Glass & Miller, 1980) reported a slight outcome advantage when therapy was conducted 
by a psychologist rather than a psychiatrist.  However, a Consumer Reports (1995) study 
on this relationship showed no differences in treatment outcomes between psychologists 
and psychiatrists, and showed better outcomes in clients seen by social workers.    Given 
the mixed or modest results regarding the impact of clinician gender and years of clinical 
experience on treatment outcomes seen in the research literature, these variables will be 
evaluated as potential moderation factors.    
 Initial analyses will report descriptive data regarding the characteristics of the 
sample and the response pattern to the LEAP Fidelity Measure.  To examine the factor 
structure of the LEAP Fidelity Measure, an exploratory principal components analysis will 
be performed and internal consistency reliabilities of the derived components will be 
calculated.  Additionally, clinician gender, years of general clinical experience, and years 
of specific clinical experience within the ACT program will be evaluated for their possible 
moderating influence on the dependent variables examined in this study.  Finally, a 
multivariate analysis of variance test will be performed to assess for differences in the two 
treatment groups.  Specifics regarding analyses follow each hypothesis below.  
 





Proposed Data Analysis: An exploratory factor analysis or principal components 
analysis of the LEAP Fidelity Measure, a 17-item survey instrument designed to measure 
the construct of adherence to the LEAP method, will be conducted to assess whether the 
measure is uni- or multi-dimensional.  Subsequent to deriving the LEAP principal 
components, the internal consistency reliabilities of the components will be evaluated 
using Cronbach’s alpha coefficient. 
 
Study Aim B: To assess and compare LEAP fidelity ratings between ACT program 
clinicians randomized into control and intervention groups.  
 
Hypothesis 1:  ACT clinicians in the intervention group will demonstrate higher 
mean ratings on the LEAP Fidelity Measure than ACT clinicians assigned to the control 
group. 
Hypothesis 2: Mean fidelity ratings will differ based on clinician gender, years of 
general clinical experience, and years of specific ACT experience, with female clinicians 
and clinicians with more general and ACT-specific clinical experience having higher mean 
fidelity ratings than male clinicians or those with less general and ACT-specific clinical 
experience. 
Proposed Data Analysis:  The principal question under examination in this study is 
whether mental health clinicians trained in LEAP do, in fact, differ with respect to their 
self-reported fidelity to this intervention protocol when compared to clinicians not trained 
in this method.  Fidelity to LEAP will be operationalized by conducting exploratory factor 





measure this construct.  The factors or components derived from this analysis will serve as 
dependent variables, i.e. “outcome” measures, in a one-way multivariate analysis of 
variance (MANOVA).   This data analytic strategy is predicated on the presumption that 
the intervention and control groups will not differ with respect to various demographic or 
background variables such as gender, years of overall clinical experience, and years of 
specific clinical experience within the ACT framework.   If the two conditions do differ on 
these characteristics, they will be used initially as controlled variables, in which case, the 
MANOVA will be replaced by one-way analyses of covariance (ANCOVAs).  In addition, 
these variables will also be evaluated as potential moderators of the expected treatment 
effects measured by the outcome variables.  Therefore, the one-way ANCOVA, if needed, 
will be “expanded” to include cross-product terms between each potential moderator and 
the ‘focal’ independent variable, treatment condition (intervention versus control).  If there 
are no background differences between intervention and control groups, the MANOVA 




















 Participants in this study are 48 mental health professionals working in independent 
Assertive Community Treatment (ACT) programs in New York State.  ACT is a treatment 
approach designed to provide comprehensive, community-based psychiatric treatment, 
rehabilitation, and support to persons with serious and persistent mental illness, such as 
schizophrenia.  The services ACT clinicians provide to clients encompass case 
management, initial and ongoing assessments, psychiatric services, employment and 
housing assistance, family support and education, substance abuse services, and other 
programs and supports critical to an individual’s ability to live successfully in the 
community.  ACT clinicians deliver these services in a variety of contexts including 
clients’ homes, community mental health clinic and hospital settings.   ACT is comprised 
of clinical professionals whose backgrounds and training include social work, 
rehabilitation, counseling, nursing, and psychiatry.  The clinical degrees that were 
represented in this sample included psychologists (i.e. Ph.D.), psychiatrists (i.e., M.D.), 
licensed social workers (i.e. LMSW and LCSW), and psychiatric nurses (i.e. RN).  Based 
on their respective areas of expertise, ACT clinicians deliver integrated services of the 
client’s choice, assist in making progress towards goals, and adjust services over time to 





clinician to every ten clients and ACT services are available 24 hours a day, 365 days per 
year, for as long as the client requires.  As an evidence-based treatment framework, ACT 
has been identified as an effective yet underutilized treatment modality for individuals with 
serious mental illness. 
The ACT Institute at the Center for Practice Innovations at the Columbia 
University Department of Psychiatry was consulted regarding recruitment of participants 
and study design.  ACT clinicians were recruited from independent community mental 
health agencies in Westchester, Duchess, Nassau, and Suffolk Counties in New York State.  
ACT programs operating in New York City were excluded from this study as these 
clinicians were in the process of implementing significant organizational changes during 
the recruitment phase.  Of the 74 ACT clinicians who were contacted regarding 
recruitment, 52 were enrolled in the study and data was collected from 48 clinicians.  Four 
clinicians were unable to participate in the study due to clinical emergencies or being 
absent from work on the day that LEAP training was held.  Background information 
regarding the 22 clinicians who chose not to enroll in the study and the 4 clinicians who 
were unable to participate in the LEAP training and data collection was not available to the 
Principal Investigator.  Of the 48 clinicians who participated in data collection, 13 were 
male and 35 were female.  The clinicians in this study reported an average of 8 years of 
overall clinical experience (mean = 7.71, sd = 5.21) and 4 years of experience within the 
ACT treatment framework (mean = 4.24, sd = 3.36). 
ACT clinicians complete a standardized assessment for each client within 30 days 
of admission, focusing on diagnosis and treatment planning, and for every six months until 





living situation, educational and vocational activities, engagement in services, incidence of 
significant events (i.e. hospitalization, homelessness, arrest), functional impairment in self-
care and social skills, and any incidence of harmful behaviors.  This information is 
monitored, evaluated and published by the New York State Office of Mental Health 
(OMH).  According to the latest OMH records dated December 2011, New York State 
ACT clients are older than age 18 with an average age of 45.  The ACT programs recruited 
for this study serve between 45 to 65 clients with an average age ranging from 44 to 47.   
The gender distribution of all New York State ACT clients are 60% male and 40% female 
compared to 51 – 59% male and 41-49% female distribution of the clients served by the 
ACT clinicians participating in this study.  Regarding racial/ethnic descent, compared to 
the overall New York State distribution of 39% African American, 37% Caucasian, 19% 
Hispanic, and 5% Asian clients, the programs participating in the current study worked 
with 13-23% African American, 57-76% Caucasian, 4-15% Hispanic, and 0-4% Asian 
clients.   
In terms of the diagnostic characteristics of all New York State ACT clients, 78% 
have a diagnosis of Schizophrenia, 16% are diagnosed with Bipolar Disorder, 5% have 
Major Depressive Disorder, and 3% have another mental illness diagnosis.  The diagnoses 
of clients served by the ACT programs recruited for this study were 62-74% with 
Schizophrenia, 20-29% with Bipolar Disorder, 3-5% with Major Depressive Disorder, and 
2-5% with another mental illness diagnosis.    Regarding other salient characteristics of the 
client population, 45% of all New York State ACT clients versus 21-36% of  clients served 





and 60% versus 39-51% had two or more psychiatric hospitalizations in the 12 months 
prior to their entry into ACT.   
The specific demographic and clinical characteristics of the client population 
served by the ACT clinicians participating in this study during the period of data collection 
were not available to the Principal Investigator.  Although collecting client outcome data 
was initially proposed, the inclusion of ACT clients in this study was not approved by the 
Teachers College Institutional Review Board.  As such, the client participation portion of 




Following standard IRB guidelines, participants were informed of the purpose of 
the study, what their participation entails, and the risks and benefits associated with 
participation. A recruitment email (see Appendix A) describing the study was distributed 
to ACT clinicians in Westchester, Duchess, Nassau, and Suffolk Counties in New York 
State before they were directly contacted by the Principal Investigator.  ACT clinicians 
were informed that they would be provided LEAP training and certification as part of 
study participation.  Clinicians were informed that if they chose to participate in the study, 
they would be randomized into either the control or intervention groups affecting the order 
of training and data collection.  For clinicians randomized into the control condition, data 
was collected prior to their participation in the LEAP training (see Figure 1 for timeline of 
study procedures for the intervention and control groups).  Prior to enrollment in the study, 





Participants were assured that their responses would be kept completely confidential, with 
no record of personal identifying information, and  
that they could withdraw from participation at any time during the study without any 
consequences to their employment.  All participants were required to give written informed 
consent (Appendix B) for enrollment in the study and were provided a copy of the signed 
document.    
Following informed consent, 52 clinicians were randomized into the control and 
intervention groups.  However, data was collected from 24 clinicians assigned to the 
control group and from 24 clinicians assigned to the intervention group.  The attrition rate 
for this study was 8% as four clinicians were unable to participate in the LEAP Training 
due to clinical emergencies or being absent from work.  As the primary purpose of this 
study is to investigate whether fidelity to the LEAP method differs between clinicians 
trained in LEAP versus clinicians not trained in LEAP, data from the intervention group 
was collected following the LEAP training seminar and data from the control group was 
collected prior to the LEAP training.  Separate training seminars for the control and 
intervention groups were conducted at host community mental health agencies.   
Intervention group ACT clinicians were provided copies of I Am Not Sick I Don’t 
Need Help! (Amador, 2010), a book authored by the developer of LEAP, Xavier Amador, 
Ph.D., outlining the core principles and intervention techniques associated with the LEAP 
method.  The intervention group ACT clinicians were asked to read the book prior to the 
training seminar.  Immediately prior to the training, information regarding the participant’s 
years of clinical experience and years within the ACT program was obtained.  The 


























an overview of the LEAP method, specific LEAP components, and role-play activities.  
The training was conducted by Dr. Amador, the author of LEAP (Amador 2000; 2007; 
2008; 2010; and 2012) and was facilitated by the Principal Investigator of this study.  
Immediately following the training, the participant’s knowledge of LEAP and skills 
acquisition was assessed using the LEAP Post-Training Questionnaire (see Appendix C). 
A description of how this measure was developed is provided below.  Incorrect responses 
on the questionnaire were reviewed to address deficiencies in knowledge during the 
training. 
Following LEAP training, intervention group participants were asked to identify 
clients in their caseload with a diagnosis of schizophrenia and were asked to employ LEAP 
interventions consistent with their clinical judgment.  Participants were asked to employ 
LEAP interventions for a minimum of two encounters per client and were informed that 
there was no minimum or maximum time required for each encounter.  Following six 
weeks of LEAP implementation, intervention group clinicians completed telephone 
interviews with the Principal Investigator assessing via self-report their fidelity to the 
LEAP method using the LEAP Fidelity Measure (see Appendix D).   Fidelity to LEAP was 
assessed six weeks following training in order to provide clinicians’ sufficient opportunity 
to employ these methods with their clients. This duration was also recommended by the 
ACT Institute to allow ACT clinicians adequate opportunity to employ LEAP interventions 
with clients. 
For the 24 participants randomized into the control group, written informed consent 
was obtained and ACT clinicians completed the LEAP Fidelity Measure via telephone 





group completed the interviews, copies of I Am Not Sick I Don’t Need Help! (Amador, 
2010) were distributed and the participants were asked to read the book prior to the 
training seminar.  The control group then participated in a five-hour LEAP training 
seminar conducted by Dr. Xavier Amador and facilitated by the Principal Investigator of 
this study, and their LEAP knowledge and skills acquisition was assessed using the LEAP 
Post-Training Questionnaire. Deficiencies in knowledge were addressed. 
It should be noted that the Principal Investigator initially proposed the use of audio- 
or video-taped clinical encounters to independently rate ACT clinicians’ fidelity to the 
LEAP method.  However, in consultation with the ACT Institute, this method of data 
collection was deemed too intrusive to the community mental health setting that ACT 
clinicians operate in.  As such, ACT clinicians’ fidelity to the LEAP method was assessed 




Listen-Empathize-Agree-Partner (LEAP; Amador, 2000, 2007, 2010; Paillot, 
Goetz, & Amador, 2009) is a clinical intervention encompassing effective communication 
strategies designed to strengthen therapeutic alliance, by-pass issues related to limited 
insight into illness, and improve treatment adherence.  Prior to LEAP training, all 
participants were provided Dr. Amador’s book I Am Not Sick, I Don’t Need Help! 
(Amador, 2010) outlining the core characteristics of LEAP.  The five-hour LEAP training 
seminar incorporated an overview of the research on the issue of poor insight into mental 





treatment adherence, frequent hospitalizations, etc.) among individuals diagnosed with 
schizophrenia, teaching of the seven LEAP interventions, and role-play activities aimed at 
demonstrating and practicing these core LEAP communication strategies.   
The LEAP principles that were discussed and role-played during the training 
seminar include: (1) Reflective Listening, (2) Empathizing, (3) Delaying, (4) The Three 
A’s, (5) Apologies, (6) Agreeing, and (7) Partnering.  According to the LEAP principle of 
Reflective Listening, practitioners demonstrate respect towards the client’s perspectives and 
choices by listening actively to their frustrations, fears and desires and reflect back what 
was communicated.  The primary purpose of this technique is to actively listen and to 
convey understanding to the client.  Within this framework, LEAP practitioners are 
encouraged to make reflective comments without commenting, disagreeing, or arguing 
regarding the content of what the client communicated.  Furthermore, particular emphasis 
is placed on making reflective statements without reacting, omitting, or reality testing 
content that is associated with the client’s delusions or hallucinations. In addition, the 
practitioner requests feedback regarding the accuracy of their reflected statements by 
asking questions such as, “Did I understand what you said correctly?” or “Did I get that 
right?”   The training seminar focuses specifically on ways to use reflective listening 
techniques to diffuse anger, lower defenses, and gain trust with the client.  This approach 
focuses on establishing safety and openness in the therapeutic relationship in an attempt to 
reduce the client’s resistance to discussing their experiences and to facilitate an accurate 
understanding of the client’s experiences, hopes and expectations.  Focusing on 
establishing trust and openness in the therapeutic relationship also increases the likelihood 





To further enhance the client’s experience of being heard and understood, the 
LEAP practitioner Empathizes with the experiences that the client shares.  The training 
seminar focuses on identifying appropriate opportunities and methods of empathizing with 
the client. The LEAP approach places particular emphasis on empathizing with any 
feelings that are associated with the client’s misperceptions or delusions without 
commenting on or challenging the content.  By considering the client’s perspectives on 
their own experiences, including their views regarding diagnosis, treatment, and goals, this 
approach aims to validate the client’s experiences without reality testing.   
It should be noted that LEAP differentiates between empathizing with a client’s 
delusions versus agreeing or encouraging delusional beliefs.  This approach acknowledges 
the deficits in insight that many chronically mentally ill individuals including those with 
schizophrenia demonstrate that contribute to ruptures in the therapeutic alliance and 
resistance towards treatment recommendations.  LEAP encourages practitioners to 
consider the client’s perspectives within the context of limited insight into their illness and 
to empathize with the client’s particular feelings regarding their illness and treatment 
within this framework.  As such, the LEAP training seminar incorporates exercises that 
encourage clinicians to connect with client’s experiences associated with insight deficits.  
For example, the rationale for clients’ reluctance to take psychiatric medications is 
explored within the context of their belief that they do not have an illness that would 
warrant such treatment.  To this end, one LEAP training exercise asks clinicians to reflect 
on whether they would take insulin injections if they knew they were not diabetic.  The 
reasons for their refusal to take insulin are discussed (i.e. the medications could be 





own physical health) and as part of the exercise, clinicians are encouraged to explore their 
emotional reactions to being advised to take medications for an illness they do not believe 
they are afflicted with.  These reflections are then associated with clients’ potential 
experiences of not being understood or heard when therapeutic interventions neglect to 
consider the client’s belief that he/she is not ill.  Through this perspective, LEAP 
practitioners are encouraged to empathize with the client’s experiences by making 
statements such as, “I can see why you don’t want to take these drugs” or “I can 
understand why you feel so angry when people don’t believe you.”   
Another core principle in LEAP is making attempts to Delay giving the client 
contrary opinions and the training seminar focuses on reviewing effective delay 
techniques.  In LEAP, specific emphasis is placed on making attempts to delay answering 
questions about the client’s delusions, psychiatric diagnosis and medications, such as, “Do 
you think I am mentally ill?” or “Do you believe me?”  Practitioners are encouraged to 
delay giving their opinion with statements such as, “I would like to understand the 
situation better before I tell you what I think, if that’s alright with you” or “I don’t think 
my opinion is as important as yours right now, is it okay if I give you my opinion at a later 
time?”  There are two rationales for utilizing this technique.  The first is to preserve and 
build on the positive therapeutic alliance developed through reflective listening and 
empathizing.  By delaying providing the client with a contrary opinion that may be 
disappointing or hurtful to them, the clinician creates the opportunity for the therapeutic 
alliance to strengthen over time.  Furthermore, when the contrary opinion is eventually 
provided to the client, a strong therapeutic alliance will minimize the likelihood of a 





technique is to hold the client responsible for repeatedly requesting the clinician’s opinion.  
By requiring the client to repeatedly ask for the clinician’s opinion regarding their 
delusional beliefs, diagnosis, or treatment recommendations, the client is rendered 
“responsible” for the solicited opinion.  For example, if the LEAP practitioner delays 
giving his/her opinion by informing the client, “I would rather not give you my opinion 
because I think it will upset you, are you sure you want to hear it?” the client’s agency in 
the relationship is increased by providing him or her with a choice.  The delay approach in 
LEAP reflects the concept that a solicited opinion is more effective than an unsolicited 
opinion.  As such, within the LEAP framework, practitioners are encouraged to only 
provide contrary opinions when solicited by the client. 
When a strong therapeutic alliance has been established and the client has requested 
the clinician’s opinion, the LEAP practitioner is encouraged to share their opinions 
regarding the client’s delusional beliefs, diagnosis, or treatment plan using one or a 
combination of the Three A’s: Apologize, Acknowledge Fallibility, and Agree to Disagree. 
LEAP practitioners may apologize for sharing a contrary opinion that may hurt or 
disappoint the client by making a statement such as, “Before I tell you what I think about 
this, I want to apologize because it might be hurtful or disappointing.  Prior to sharing a 
contrary opinion with the client, the LEAP practitioner may acknowledge the fallibility of 
his or her opinion by making a statement such as, “I want to acknowledge that I could be 
wrong about this because I don’t always have the right answer.”  Finally, the LEAP 
practitioner may agree to disagree on their difference of opinion with the client by stating, 
“I hope that we can just agree to disagree on this because I respect your point of view and I 





confrontations that may invalidate the client’s experiences and to avoid eliciting a 
defensive reaction from the client. The training seminar places particular emphasis on 
determining appropriate situations to effectively use the Three A’s and to role-play 
practitioners’ use of apologies, acknowledging fallibility, and agreeing to disagree.   
The use of Apologies is not only emphasized within the context of prefacing the 
communication of potentially hurtful information (i.e. contrary opinions).  In LEAP, 
apologies are frequently used to communicate humility on the part of the clinician and to 
convey respect for the client’s feelings and opinions. As apologizing for one’s opinions is 
not common in general clinical practice, trainees are encouraged to discuss their reactions 
to this specific technique during the LEAP training seminar.  The seminar also places 
particular emphasis on identifying situations where empathic apologies may be helpful. 
For example, clinicians may use apologies as a means of empathizing with a negative side 
effect of medication by stating, “I’m so sorry you have to deal with the weight gain 
associated with your medications.” The rationale of using apologies as a clinical 
intervention is to increase trust in the therapeutic relationship by encouraging honest 
communication between client and clinician.   
Identifying areas of Agreement is another core technique defining the LEAP 
approach.  Rather than focusing on areas of disagreement with the client, the LEAP 
practitioner attempts to further strengthen the therapeutic alliance by emphasizing the goals 
shared by both the client and the clinician.  To this end, the clinician is encouraged to 
normalize the client’s experience by making statements such as, “I would feel the same 
way if I were in your shoes,” and to focus on the client’s perceived problems and 





client and correcting the client’s misconceptions regarding treatment options can further 
facilitate discussion of shared goals.  The LEAP practitioner is encouraged to reflect back 
and emphasize the perceived benefits of treatment by making a statement such as, “If I 
have it right, you’re saying that when you stay on the medication you sleep better and fight 
less often with your family.”  By focusing on the client’s perceptions of the problem, the 
LEAP practitioner avoids confrontations, increases the client’s sense of agency, and 
emphasizes areas of common ground between the client and clinician.  
Practitioners of LEAP also strive towards collaboration with the client by 
establishing mutually agreed-upon goals and Partnering or collaborating in the pursuit of 
achieving these goals.  To this end, clinicians are encouraged to articulate the shared goals 
to the client, develop concrete plans to achieve these goals, and engage in an ongoing 
assessment of progress made towards these goals.  Special emphasis is placed on 
acknowledging the personal choices of the client and respecting that the client is 
responsible for the decisions they make in life.  
The overarching goal of LEAP is to develop a trusting and accepting environment 
that enables the practitioner to become more persuasive in his or her treatment 
recommendations to the client.  The specific techniques associated with each core principle 
were discussed and role-played during the LEAP training seminar.  Immediately following 
the LEAP training seminar, participants’ acquisition of knowledge and skills was assessed 
using the LEAP Post-Training Questionnaire.  Each item on the questionnaire was 









LEAP Post-Training Questionnaire 
The LEAP Post-Training Questionnaire (LPTQ) was developed by the founder of 
LEAP, Xavier Amador, Ph.D., in collaboration with Lisa Hunter, Ph.D. and Elizabeth 
Pappadopolis, Ph.D. from the New York State Psychiatric Institute (NYSPI).  The LPTQ 
assesses participants’ knowledge following the LEAP training seminar.  The 31-item 
measure consists of 24 “True” or “False” items assessing specific LEAP principles such as 
“When faithfully following the LEAP approach, you should provide frequent and gentle 
reality testing,” and “When faithfully following the LEAP approach, you should reflect 
back what you have heard and ask the person whether or not you understood him 
correctly.”  The measure also consists of 4 open-ended items assessing the Reflective 
Listening and Delaying Opinions components of the LEAP approach such as “In the space 
below, reflect back the following statement: ‘These medications are making me hear 
voices and I need your help suing the hospital.  You’ve got to help me because no one else 
will. Will you help me?’” One item on the measure provides 10 possible delay tactics and 
asks the participant to circle the tactics that are aligned with the LEAP approach.  The 
measure includes 2 open-ended items requesting feedback regarding the LEAP training 
seminar and the LEAP approach.  The measure also includes one item asking whether the 
participant feels comfortable employing LEAP principles with clients following 
participation in the LEAP training seminar and self-study of I Am Not Sick, I Don’t Need 





 Psychometric properties of this measure have not been reported as its primary 
purpose is as a training tool designed to reveal misconceptions and stimulate discussion 
during the training session.   
 
LEAP Fidelity Measure 
The LEAP Fidelity Measure was developed by the Principal Investigator of this 
study in collaboration with Dr. Xavier Amador.  The 17 items of the measure reflect the 
core principles of LEAP, including Reflective Listening, Delaying, The Three A’s, 
Apologizing, Empathizing, Agreeing, and Partnering, and were derived from Dr. Amador’s 
book, I Am Not Sick, I Don’t Need Help! (2010) and the specific items were developed in 
consultation with Dr. Amador. The self-report measure asks participants to rate their 
fidelity to LEAP principles using a 5-point Likert scale (1 = “Never,” 3 = “Sometimes,” 5 
= “Always”).  Four items were developed to assess the Reflective Listening LEAP 
principle including “Listened to the client’s frustrations, fears and desires” (LFM01), 
“Listened to the client’s discussions of delusions or hallucinations without reacting, 
omitting, or reality testing” (LFM02), “Reflected back to client what was heard” (LFM03), 
and “Requested feedback from client regarding the accuracy of my reflected statements” 
(LFM04).  The three items rating the Delaying principle include “Made an attempt to delay 
giving a contrary opinion” (LFM05), “Only gave contrary opinions with the client’s 
permission” (LFM07), and “Did not offer contrary opinions unless necessary” (LFM08).  
Item 6, “Preceded contrary opinions using 1 or more of the 3 A’s (Apologize, 
Acknowledge Fallibility, Agree to Disagree)” (LFM06), was used to assess the clinician’s 





from the client’s” (LFM09), was used to assess the Apologizing LEAP principle. Four 
items were developed to assess the LEAP principle of Empathizing with the client and 
included the following items: “Empathized with the client’s frustrations, fears and desires” 
(LFM10), “Empathized with the client’s feelings about their illness or diagnosis” 
(LFM11), “Empathized with the client’s feelings about treatment” (LFM12), and 
“Normalized the client’s feelings” (LFM13).  The two items assessing the Agreeing LEAP 
principle were “Actively identified goals that both my client and I agree on” (LFM14) and 
“Articulated shared goals with client” (LFM15). Furthermore, the two items developed to 
assess the Partnering LEAP principle were “Developed a plan to achieve shared goals with 
client” (LFM16) and “Engaged the client in an ongoing assessment of progress made 






















The participants in this study are mental health clinicians (n = 48) from Assertive 
Community Treatment (ACT) programs working in independent community agencies in 
New York State who were randomly assigned to either the intervention condition (i.e. the 
LEAP training condition) or the control condition. As seen in Table 1, most of these 
clinicians are females (73%) with approximately eight years of general clinical experience 
(mean = 7.71, sd = 5.21) and slightly more than four years of specific clinical experience 
within the ACT treatment modality (mean = 4.24, sd = 3.36).  The majority of the mental 
health clinicians represented in this sample are licensed social workers (LCSW: 27.1%; 
LMSW: 41.7%) followed by psychiatric nurses (RN: 20.8%), psychiatrists (M.D.: 8.3%), 
Table 1 
Descriptive Data for All Study Participants (n = 48) 
 
Frequency 
(Percent) Mean SD Minimum Maximum 
Gender      
     Female 35 (72.9)     
     Male 13 (27.1)     
Clinical Degree      
     Psychologist (Ph.D.) 1 (2.1)     
     Psychiatrist (M.D.) 4 (8.3)     
     Social Worker (LCSW) 13 (27.1)     
     Social Worker (LMSW) 20 (41.7)     
     Psychiatric Nurse (RN) 10 (20.8)     
Years of General Clinical Experience  7.71 5.21 1.00 20.00 






and a psychologist (Ph.D.: 2.1%).   
Prior to evaluating the effect of the intervention, the treatment and control groups 
were tested for possible “baseline” differences in the three background variables available 
in the study, ( i.e., gender, years of general clinical experience and years of specific 
experience with ACT).  These descriptive statistics and results are presented in Table 2. 
Given the random assignment of subjects to the treatment and control conditions, it was 
hypothesized that no such differences would be found.  
Table 2 
Descriptive Data for All Variables Comparing Control and Intervention Groups 
 Control Group (n = 24) Intervention Group (n = 24)  
 Mean SD Mean SD t 
Years of General Clinical 
Experience 7.48 4.98 7.94 5.53 -.30 
Years of Specific ACT 
Experience 4.23 3.07 4.25 3.72 -.02 
Categorical Variable Frequency Percent Frequency Percent Χ2 
Gender     .95 
     Female 16 66.7% 19 79.2%  
     Male 8 33.3% 5 20.8%  
 
A chi-square test was conducted in order to test for possible differences in the 
gender distributions of the treatment and control groups. As shown in Table 2, no 
significant difference in the gender distribution was found (χ2 = 0.95 (1), p = .33). T-tests 
were next conducted in order to test for possible mean differences between the treatment 
and control groups on years of general clinical experience and years of clinical experience 
in ACT. As also shown in Table 2, the treatment and control groups did not differ on either 
of these measures (years of general clinical experience, t = -.30, df = 46, p = .76; years of 





 There was not enough variability in this sample to discern whether the distribution 
of clinical degree differed between the control and intervention groups, as the majority of 
the clinicians represented in this sample held LCSW (27.1%) and LMSW (41.7%) clinical 
social work degrees.   
 
Factor Structure of the LEAP Fidelity Measure 
 
The primary purpose of this investigation is to evaluate the degree to which 
clinicians trained in the LEAP method can demonstrate fidelity to the intervention. In order 
to address this question, the 17 items of the LEAP Fidelity Measure (see Appendix IV), a 
self-report measure, were constructed to reflect the “core” principles of the LEAP method.  
Given the size of the available sample, an exploratory approach was taken to evaluate the 
dimensionality of the LEAP Fidelity Measure items. More specifically, the 17 items, which 
were completed by all study participants, were submitted to a principal components 
analysis using an oblique method of rotation (promax).  
Visual inspection of the scree plot associated with this principal components 
analysis suggests that either a two-component or three-component solution best 
characterized the number of summary dimensions in the data.  Consistent with the scree 
plot, the analysis extracted three components that “explained” or recovered 68% of the 
variance in the set of 17 items. As item LFM08, “Did not offer contrary opinions unless 
necessary,” loaded on both the first and second components, this item was excluded from 





The first principal component is labeled “Reflective Listening, Delaying, and 
Opining” as this set of items reflects techniques that can be conceptualized as relatively 
unique to the LEAP approach.  The eight items in this component encompass reflective 
listening without reacting, omitting or reality testing psychotic content, requesting  
feedback regarding the accuracy of reflected statements, making attempts to delay 
providing the client with a contrary opinion, and preceding contrary opinions with 
apologies, acknowledging the clinician’s own fallibility, or agreeing to disagree. These 
items represent the Listening, Delaying, the Three A’s, and Apologizing LEAP principles. 
The second component is labeled “Partnering on Shared Goals” as the four items that 
comprise this component measures the clinician’s ability to identify goals that both the 
client and clinician can partner on, and to communicate and assess progress made towards 
these shared goals with the client. The items reflected in this component represent the 
Agreeing and Partnering LEAP principles.  Finally, the third component, labeled “Client-
Centered Listening and Empathizing” is comprised of four items that emphasize listening 
to and empathizing with the client’s frustrations, fears and desires, as well as their feelings 
about their illness, diagnosis, and treatment.  
Table 4 presents the descriptive statistics for the three principal components. 
Subsequent to deriving the three LEAP principal components, the internal consistency 
reliabilities of the components were generated using Cronbach’s alpha coefficient. For the 
first principal component, Reflective Listening, Delaying, and Opining, the internal 
consistency reliability coefficient is (α =) .93. For the Partnering on Shared Goals 
component, the reliability coefficient is (α =) .90, and, finally, for the third Client-Centered 







Rotated Pattern Matrix for Seventeen-Item LEAP Fidelity Measure 
  Components 
 
 1 2 3 
LFM01 Listened to the client’s frustrations, fears and desires. .32 -.53 .58 
LFM02 Listened to client’s discussions of delusions or 
hallucinations without reacting, omitting, or reality testing. .81   
LFM03 Reflected back to client what I heard. .88   
LFM04 Requested feedback from client regarding the accuracy of 
my reflected statements. .97   
LFM05 Made attempts to delay giving opinions that are contrary to 
the client’s. .72   
LFM06 Preceded contrary opinions with an Apology, 
Acknowledging my Fallibility, or Agreeing to Disagree (3 
A’s). 
.52 .42  
LFM07 Only gave contrary opinions with the client’s permission. .60 .40  
LFM08 Did not offer contrary opinions unless necessary. .47 .36  
LFM09 Apologized for opinions that differ from the client’s. .61 .37  
LFM10 Empathized with the client’s frustrations, fears and desires.   .58 
LFM11 Empathized with the client’s feelings about their illness or 
diagnosis.   .72 
LFM12 Empathized with the client’s feelings about treatment.   .82 
LFM13 Normalized the client’s feelings. .73   
LFM14 Actively identified goals that both my client and I agree on.  .80  
LFM15 Articulated shared goals with the client.  .81  
LFM16 Developed a plan to achieve shared goals with the client.  .83  
LFM17 Engaged the client in an ongoing assessment of progress 
made toward the shared goals.  .87  
  Extraction Method: Principal Components Analysis. 
 Rotation Method: Promax with Kaiser Normalization. 










With respect to the Reflective Listening, Delaying, and Opining component, the 
sample, as a whole, reports using these particular techniques “Sometimes”, on average 
(mean = 3.19, sd = .96). A similar level of endorsement characterizes the second principal 
component, Partnering on Shared Goals (mean = 3.33, sd = 0.87). However, there is 
noticeable increase in the level or degree of endorsement of the Client-Centered Listening 
and Empathizing component, reflecting average responses between “Often” and “Always” 
(mean = 4.51, sd = 0.37).  It should also be noted that the range of responses pertaining to 
this component was constricted to the upper range of the 5-point Likert scale, reflecting 
responses between “Sometimes” and “Always.”  Conversely, the sample did not endorse 
responses in the “Never” or “Rarely” range on items comprising the Client-Centered 
Interventions component. 
Table 4 
Descriptive Statistics for LEAP Fidelity Measure Principal Components 
 
Number of 
Items Mean SD Minimum Maximum Alpha 
Component 1       
     “Reflective Listening,     
           Delaying and Opining” 8 3.19 .96 1.38 4.63 
.93 
Component 2       
     “Partnering on Shared Goals” 4 3.33 .87 1.00 5.00 .90 
Component 3       
     “Client-Centered Listening 
          and Empathizing” 




Analysis of Hypotheses 
  
For the purpose of evaluating the effect of the intervention, a one-way multivariate 
analysis of variance (MANOVA) was used. In this analysis, the independent variable was 





participants. The dependent variables were the three principal components. Table 5 
presents the findings from this analysis. The multivariate F statistic was statistically 
significant indicating that the treatment and the control groups differed significantly on the 
set of the three outcome measures (F = 62.50, (3,44), p < .001). In order to “locate” which 
of the three components the treatment and controls differ on, the univariate results were 
examined.  As seen in the table, the treatment and the control groups differed significantly 
on the first two components. With respect to the first of these components, Reflective 
Listening, Delaying and Opining, the treatment group’s mean was significantly higher than 
the control group’s mean (treatment group mean = 4.03, control group mean = 2.35, F = 
161.85, (1,46), p < .001).  Similarly, with regard to the second component, Partnering on 
Shared Goals, the treatment group’s mean was, again, significantly higher than the control 
group’s mean (treatment group mean = 3.97, control group mean = 2.69, F = 58.20, (1,46), 
p < .001). The treatment and the control groups did not significantly differ with respect to 
their means on the third component, Client-Centered Listening and Empathizing (F = .46, 
(1,46), p = .50).  
Table 5 
Multivariate Analyses of Variance (MANOVA) Evaluating Fidelity Ratings on LEAP Principal 
Components for Control and Intervention Groups  
 
Control Group 
(n = 24) 
Intervention Group 
(n = 24) 
 
 
 Mean SD Mean SD F 
Partial Eta 
Squared 
Principal Component 1       
     “Reflective Listening, Delaying 
          and Opining” 2.35 .50 4.03 .41 161.85*** .78 
Principal Component 2       
     “Partnering on Shared Goals” 2.69 .69 3.97 .45 58.20*** .56 
Principal Component 3       
     “Client-Centered Listening 
          and Empathizing” 4.47 .40 4.54 .34 
.46 .01 





Statistical significance tests address an important question, i.e., whether an effect is 
not zero, or in the case of this particular study, whether the difference in mean LEAP 
fidelity ratings between the control and treatment conditions is not zero. However, once the 
statistical significance tests indicate that an effect is not zero, understanding the magnitude 
of the difference between groups helps determine whether the effect size is “meaningful.” 
In this study, the partial eta-squared statistic (η2) was used to determine the magnitude of 
the effect size. Drawing upon Cohen’s (1988) recommendations for the interpretation of 
mean differences in effect size terms, partial eta-squared statistics of .01 are considered 
“small” effects, .06 are considered “moderate” or “medium” in magnitude, and partial eta-
squared statistics greater than .14 are considered “large” (Cohen, 1988, p. 283).  As seen in 
Table 5, the partial eta-squared statistics for the Reflective Listening, Delaying and 
Opining (η2 = .78) and Partnering on Shared Goals (η2 = .56) LEAP components can be 
characterized as very large effect sizes.  As the statistical significant test for the Client-
Centered Listening and Empathizing component was not significant, the eta square statistic 
for this component was not interpreted. 
Table 6 
Simple Correlations Between “Baseline” and Outcome Variables  
 Gender 
Years of General 
Clinical Experience 
Years of Specific  
ACT Experience 
Outcome Variables    
     “Reflective Listening, Delaying 
          and Opining” -.11 -.26 -.26 
     “Partnering on Shared Goals” -.18 -.06 -.23 
     “Client-Centered Listening 
          and Empathizing” .28* -.21 
-.27 
 *p < .05. **p < .01. ***p < .001.   
There were no significant differences between the intervention and control groups 
based on gender, years of general clinical experience, and years of specific ACT 





non-significant. Although not part of the formal hypotheses, a post hoc analysis assessing 
potential correlations between these “baseline” variables and the outcome variables (the 
three LEAP Fidelity Measure principal components: Reflective Listening, Delaying and 
Opining; Partnering on Shared Goals; and Client-Centered Listening and Empathizing) 
was conducted.  The Pearson correlations are presented in Table 6.  In terms of gender, 
although there was a general trend for female clinicians to report higher fidelity to 
Reflective Listening, Delaying and Opining (r = -.11) and Partnering on Shared Goals (r = 
-.18), this gender association was not statistically significant.  However, there was a 
significant gender correlation on clinicians’ reports of fidelity to the Client-Centered 
Listening and Empathizing component (r = .28, p = .05), with male clinicians reporting 
greater fidelity to this set of interventions.  Additionally, although there was a general 
trend for clinicians with more general clinical experience and specific ACT experience to 
be less likely to report fidelity to Reflective Listening, Delaying and Opining (r = -.26), 
Partnering on Shared Goals (r = -.06), and Client-Centered Listening and Empathizing (r = 
-.27), these associations were not statistically significant.   
Furthermore, when the relationships between these variables were assessed based 















The primary purpose of this study was to assess ACT clinicians’ fidelity to the 
LEAP method, a set of clinical interventions that address issues of poor insight, therapeutic 
alliance, and treatment adherence prevalent in the schizophrenia population.   A secondary 
purpose of this study was to examine the factor structure and psychometric properties of a 
measure developed to examine the core components comprising the LEAP approach.  
Study results indicated a three factor structure of the LEAP Fidelity Measure that were 
labeled “Reflective Listening, Delaying and Opining,” “Partnering on Shared Goals,” and 
“Client-Centered Listening and Empathizing.”  Analyses revealed significantly higher 
LEAP fidelity ratings among clinicians in the intervention group in the Reflective 
Listening, Delaying and Opining and Partnering on Shared Goals components when 
compared to the control group clinicians.  No significant differences were found between 
the two groups on the Client-Centered Listening and Empathizing LEAP component.  
Although no differences were found based on gender or years of clinical experience 
between the two groups, a post hoc analysis evaluating the effect of baseline characteristics 
on the three LEAP components revealed a modest correlation between gender and the 
Client-Centered Listening and Empathizing component.  The specific results are discussed 
below within the context of existing literature.  From clinical and mental health service 
perspectives, these results suggest that dissemination and implementation of LEAP is 





Patterns of LEAP Fidelity Ratings 
 
The Three LEAP Fidelity Measure Principal Components 
 The results of this study indicate that mental health clinicians who participated in a 
one-day training on LEAP demonstrated a significantly higher level of fidelity to this 
clinical intervention when compared to those who did not receive the training.  Although it 
was hypothesized that the intervention group would demonstrate higher fidelity ratings on 
all components of the LEAP method, the ACT clinicians who were assigned to the LEAP 
intervention group reported higher fidelity to the Reflective Listening, Delaying and 
Opining and Partnering on Shared Goals components of LEAP but did not differ from the 
control group on the Client-Centered Listening and Empathizing LEAP component.   
These findings may illustrate components that are unique to LEAP interventions 
versus those that represent a fundamental theoretical framework that is common across 
psychotherapeutic approaches. The Reflective Listening, Delaying and Opining and the 
Partnering on Shared Goals components may represent novel clinical intervention 
techniques that are particularly unique to the LEAP method and differentiate LEAP from 
other psychotherapeutic modalities.  These components reflect the LEAP interventions that 
acknowledge the neurologically-based insight deficits in schizophrenia by putting aside 
improving clients’ insight into their illness as a primary goal of therapy. Clinical 
interventions that do not emphasize increasing insight as a treatment goal may be 
particularly relevant to this population as research suggests that improvements in overall 
symptom severity and treatment adherence among individuals with schizophrenia do not 





2000; Jorgensen, 1995; Rathod, Kingdon, Smith, & Turkington, 2005).  Moreover, 
confronting insight deficits in this population may, in fact, prove detrimental to developing 
a strong therapeutic alliance which may consequently contribute to service disengagement 
and poor treatment outcomes prevalent among individuals diagnosed with schizophrenia. 
Thus, the LEAP approach may differ from interventions derived from 
psychodynamic and psychosocial perspectives that emphasize the importance of gaining 
insight into one’s illness and the psychological processes that contribute to one’s 
difficulties as a necessary step in facilitating meaningful therapeutic change (for review, 
see Wampold et al., 2007).  Rather, these particular LEAP interventions place special 
emphasis on bypassing issues related to these deficits within the therapeutic relationship by 
accurately reflecting the experiences of the client, refraining from reality testing, and 
partnering with the client on treatment goals that do not confront his or her poor insight 
into mental illness.  Therefore, the suggestion that these components are reflective of 
techniques that are unique to the LEAP method helps explain the finding that the 
intervention group that received LEAP training demonstrated significantly higher levels of 
fidelity to these specific intervention strategies when compared to clinicians who were not 
trained in LEAP. 
Anecdotal evidence also supports this conclusion. During phone interviews, several 
participants from the intervention group commented on the qualitative changes they 
experienced in the therapeutic alliance with particularly difficult clients. It should be noted 
that these clinicians attributed this change in the therapeutic alliance to their use of LEAP 
techniques that de-emphasize “trying to convince” clients that they have a mental illness.  





reflective listening and using apologies, acknowledging fallibility, and agreeing to disagree 
despite the initial discomfort and “skepticism” they had towards these techniques during 
the LEAP training.  However, these clinicians reported that these techniques in particular 
have been effective in conveying respect towards the client’s experiences and in helping 
the clinician focus on the client’s perspectives, rather than working towards their own 
personal or professional “agendas.”  These clinicians also reported feeling less “burnt out” 
by clients with severe insight deficits as the LEAP approach provided them techniques to 
bypass issues related to poor insight in treatment and to identify goals that both the client 
and clinician are motivated to work towards achieving.   
In contrast to the intervention group, the clinicians assigned to the control group 
expressed general skepticism regarding LEAP techniques during the phone interviews that 
occurred prior to the training.  Several clinicians shared particularly strong negative 
reactions to the use of the Three A’s (apologizing, acknowledging fallibility, and agreeing 
to disagree) by making statements such as, “I would never apologize for my professional 
opinion” or expressed concern that using these techniques would jeopardize their 
“credibility” as clinicians.  Furthermore, several clinicians in this group also expressed 
their reluctance to use LEAP interventions associated with delaying providing the client 
with a contrary opinion as they felt that these techniques may be potentially “evasive” and 
“manipulative.”  As such, anecdotally, clinicians in the intervention and control groups 
expressed varied perspectives and degrees of openness towards LEAP techniques.   
 In contrast to the Reflective Listening, Delaying and Opining and Partnering on 
Shared Goals components that may be unique to the LEAP method, the aspects of the 





component may illustrate a clinical stance that is common across different psycho-
therapeutic approaches.  This component encompasses techniques focusing on non-
directive listening and empathizing with a client’s fears, frustrations, and desires, as well 
as their feelings towards their diagnosis and treatment.  This finding is consistent with the 
suggestion that the client-centered approaches of empathy, genuineness and positive regard 
are critical aspects of a positive therapeutic alliance that facilitate the healing process in 
therapy and are fundamental aspects that have become integrated across therapy modalities 
(Farber 2007; Horvath, 2001; Stricker & Gold, 1996; Watson, 2007).  As such, these 
aspects are not particularly unique to the LEAP approach and may represent what Carl 
Rogers called the “necessary and sufficient” components (1957, p. 87) that have become 
the generalized foundation of a positive therapeutic stance explaining the high fidelity 
ratings to this component demonstrated across the intervention and control groups.   
 
Gender and Years of Clinical Experience 
 The results of this study revealed that the two groups were comparable based on the 
distribution of gender, years of general clinical experience, and years of specific ACT 
clinical experience.  Furthermore, no significant interaction effects were found between the 
intervention and control groups on these baseline variables and LEAP fidelity ratings on 
the three principal components.   
Although an overall gender difference in the three LEAP components was not 
specifically hypothesized, the finding that male clinicians reported significantly higher 
levels of fidelity to the Client-Centered Listening and Empathizing component presents an 





females may be generally more empathic than males (Eisenberg & Lennon, 1983; Gilligan, 
1993; Jordan, 1995; Lennon & Eisenberg, 1987), there are few studies examining gender 
differences in self-reported empathy among mental health clinicians.  In a study of self-
reported and observed empathy among therapists, Hatcher and colleagues (2005) found 
that not only did female therapists rate themselves as significantly higher on empathic 
concern and perspective taking, they were also observed to demonstrate responses that 
were rated as more empathic than their male counterparts.  However, both male and female 
therapists rated empathic interventions as extremely important to their clinical work. 
Though it is difficult to identify a definitive explanation for the modest gender difference 
found in this study, perhaps the male clinicians working with the chronically mentally ill 
client population is a self-selected group with a particularly high capacity for empathy.  
Furthermore, it may be possible that male clinicians may feel the need to 
“overcompensate” on characteristics, such as empathy, that are socially viewed to be 
stereotypically female.  
 The results of this study also indicate that there was a general trend for clinicians 
with greater years of general clinical experience and specific experience within the ACT 
framework to report lower levels of fidelity to all three components of LEAP.  Although 
this trend was not statistically significant, it poses an interesting question regarding 
clinicians’ openness towards learning and implementing new clinical interventions.  
Although few studies have investigated the relationship between clinician years of 
experience and their willingness towards new clinical practices, existing research supports 
the general trend that clinicians with relatively limited experience tend to be more open to 





Rentsch & Klimoski, 2001).  Aaron (2005) suggests that novice clinicians may have more 
malleable knowledge structures that allows for flexibility facilitating integration of newly-
learned clinical skills into their existing clinical repertoire.   
 
Limitations of Study 
 
This study has a number of limitations.  The sampling method used in this study 
may limit the generalizability of the results.  ACT clinicians working in Westchester, 
Duchess, Suffolk, and Nassau counties in New York State were recruited for this study.  
Although 65% of the ACT clinicians in these counties participated in the study, 
demographic information on the 35% who chose not to participate in the study was not 
available to the Principal Investigator.  Thus, possible differences between these two 
groups of clinicians as well as the possibility of a non-response bias could not be 
evaluated.  Furthermore, as all ACT clinicians in New York State were not recruited for 
participation, the clinicians in this study may not be a representative sample and the results 
of this study may not be generalizable to the larger group of New York State ACT 
clinicians or the general population of mental health clinicians. 
The sample size, while large enough to provide sufficient statistical power for the 
analyses included in this study, was too limited to conduct a Confirmatory Factor Analysis 
(CFA) to examine the dimensions of the LEAP Fidelity Measure.  Ideally, a CFA would 
have provided the optimal measurement strategy since the seventeen items were written to 
reflect the seven, theoretically-derived treatment principles proposed by the LEAP founder 





available sample and the data requirements for the CFA, this analysis was infeasible. 
Therefore, a more exploratory approach was taken to evaluate the dimensionality of the 
seventeen LEAP Fidelity Measure items. Furthermore, a larger sample size may have 
captured a more heterogeneous distribution of clinical degree allowing an examination of 
this background characteristic as a potential moderator variable affecting clinicians’ 
fidelity to the LEAP approach.  In addition, the inclusion of this clinician characteristic in 
the post hoc analysis may have yielded patterns of intervention fidelity informing future 
research into the LEAP method. 
A blind experimental study design may have improved the reliability and validity 
of this study as the Principal Investigator who was not blind to the study hypotheses 
conducted all of the recruitment and data collection activities.  There is a risk of 
experimenter bias influencing participants’ responses in this study as the Principal 
Investigator may have inadvertently communicated differing response expectancies to the 
intervention and control groups. This risk is further amplified as the Principal Investigator 
also facilitated the LEAP training for the participants in this study. However, Rosenthal 
and Rosnow (1991) suggest that measuring the dependent variable in a setting that differs 
from the training environment and removed in time from the treatment may minimize the 
experimenter-subject artifacts in experimental settings.   
The findings of this study are also limited by the potential biases of self-report as 
there are demand characteristics inherent in the data collection procedure associated with a 
positive response bias. There was no direct observation of clinicians’ actual fidelity to 
LEAP, which could be very different from reported practices, particularly due to the 6-





The literature in treatment fidelity research encourages the use of objective ratings via in-
person evaluations as well as audiotaped or videotaped clinical interactions (for review, see 
Bellg et al., 2004).  However, the intrusiveness of this method and the possible obstacles 
this approach poses for study recruitment efforts and the impact of experimenter 
involvement in clinical interactions has been acknowledged (Naleppa & Cagle, 2010).  The 
focus of efficacy studies is on the demonstration of a direct causal relationship between an 
intervention and outcomes, requiring controlled environments and strict adherence to 
standardized protocols thereby increasing internal validity and replicability (Nathan, Stuart 
& Dolan, 2000).  However, when studies explore the effectiveness, feasibility, and 
adoptability of an intervention, a singular focus on standardized procedures may be 
counterproductive as this approach is invariably at odds with the complicated nature of the 
practice of psychotherapy in “real world” settings.   The translation of evidence-supported 
interventions into practice settings often require modifications to the original protocol 
while also acknowledging the variability in diagnosis, comorbid psychopathology and 
duration of illness among the client population in addition to the fact that treatment 
method, frequency and duration are driven by clinical considerations rather than 
standardized procedures in clinical settings (Castro, Barrera, & Martinez, 2004; Green & 
Glasgow, 2006; Naleppa & Cagle, 2010).   
This study presents areas of improvement when compared to the BCC best 
practices guidelines for establishing treatment fidelity in clinical intervention research 
(Bellg et al., 2004; Borrelli et al., 2002; 2005). According to the BCC recommendations 
for the Design category, this study provided a clear description of the study design and 





study intervention in addition to minimizing the possibility of contamination of the 
intervention and control groups by preventing overlap in study activities between these two 
groups.  This study addressed the Training guidelines presented by the BCC through 
careful reporting of training methods as well as measurement of participant skill 
acquisition through the use of the role-play activities during LEAP training and assessment 
via the LEAP Post-Training Questionnaire.  However, maintenance of these skills was not 
promoted through ongoing supervision of LEAP techniques in the current study.  The BCC 
also recommends objective monitoring of Delivery of interventions through independent 
confirmation of techniques implemented by clinicians. Furthermore, in their 
comprehensive review of empirical evaluation of training clinicians in evidence-based 
therapies, Beidas and Kendall (2010) suggest that the “gold standard” of training include a 
workshop, treatment manual, and clinical supervision.   Research indicates that although 
didactic training is a necessary component of dissemination of empirically-supported 
interventions, there is little evidence of their effect on clinicians’ ability to implement the 
techniques they were trained in (Beidas & Kendall, 2010; Carroll et al., 2006; Carroll, 
Martino, & Rounsaville, 2010).  Therefore, augmenting the LEAP didactic seminar with 
additional training components including videotapes exemplifying the optimal use of 
LEAP strategies, a treatment manual, and ongoing clinical supervision would approximate 
what is considered to be standard practice in intervention research.  In addition, although 
the use of audio- or video-taped sessions was initially proposed as the ideal strategy to 
assess clinicians’ fidelity to LEAP interventions, these methods could not be implemented 





by the ACT Institute.  As such, although a less reliable measure, clinicians’ ratings of 
fidelity to LEAP were assessed via a self-report measure. 
Another limitation of this study is that the control condition did not include a 
comparable duration of training in an alternative intervention.  The inclusion of a control 
group in psychotherapy research generally proposes the use of a placebo design or an 
alternative treatment design that does not emulate the active ingredients of the intervention 
that is being evaluated (Nathan, Stuart & Dolan, 2000).  The literature on the 
recommended standards of efficacy and effectiveness research raises the question 
regarding whether an inert placebo control, although the control condition of choice in 
pharmacological research, is possible to achieve in psychotherapy studies as most control 
conditions encompass even non-specific benefits.  Therefore, researchers support the use 
of a comparable treatment with minimal overlap with the intervention condition that is the 
focus of the study (for review, see Nathan, Stuart & Dolan, 2000).  Despite these 
recommendations, the use of an alternative treatment, such as mindfulness training, as a 
control condition was not feasible for this particular study. The participants in the study 
were specifically interested in acquisition of LEAP skills and the Executive Directors 
overseeing all training activities at the independent ACT agencies would not accommodate 
an additional day of training for this control condition as the control group clinicians were 
also provided LEAP training at the conclusion of the study.   
Although the literature on treatment fidelity underscores the importance of 
standardizing core intervention elements towards the larger goal of developing and 
disseminating effective treatments, Naleppa and Cagle (2010) also encourage researchers 





protocols to maximize feasibility and adoptability in real-world practice settings.  Despite 
the limitations of using self-report measures in evaluating treatment fidelity, the feasibility 
and value of conducting research in a “real-world” clinical setting while minimizing the 
intrusiveness or obtrusiveness of study participation was prioritized in this pilot study.  
However, the influence of a social desirability effect on the participants’ responses was 
mitigated by guaranteeing confidentiality of responses and by encouraging respondents to 
answer questions as honestly as possible.  Furthermore, the use of a telephone interview to 
administer the self-report measure may mitigate some of the demand characteristics of this 
method of data collection (Rosenthal & Rosnow, 1991).   
 
Implications for Future Research 
 
 Research suggests that efforts to disseminate and implement evidence-based 
practices must take into account the complexities of mental health service in “real world” 
settings (Fraser & Greenhalgh, 2001; Hasenfeld, 1992; Henggeler & Schoenwald, 2002; 
Jankowicz, 2000; Simpson, 2002).  As such, one of the strengths of the current study is 
that it focused on “real world” clinicians who work in community mental health settings.  
In that respect, this study differs from the vast majority of extant research of manualized 
interventions primarily involving doctoral-level clinicians (Aarons, Woodbridge, & 
Carmazzi, 2003; Cohen, Sargent & Sechrest, 1987).  It should be noted that the majority of 
the clinicians in this study were licensed social workers and there was only one 
psychologist who was a participant in this study.  The relatively low distribution of 





and these non-doctoral-level providers are likely to be essential agents of widespread 
delivery of evidence-based practices (Aarons, Woodbridge, & Carmazzi, 2003).   
 Although this study focused on the application of LEAP with clients diagnosed 
with schizophrenia, LEAP was primarily developed as a means of strengthening the 
therapeutic alliance and can be implemented in a variety of clinical settings and with 
various forms of psychopathology.  For instance, LEAP strategies are applicable to a 
variety of individuals seeking help with a particular mental illness, regardless of other co-
occurring conditions or the duration of illness.  Moreover, the applicability of LEAP has 
implications even broader than clinical settings. Many family members have attended 
LEAP trainings to learn skills for the purpose of effectively managing the challenges of 
having a mentally-ill loved one and law enforcement officers have also been trained in 
LEAP to de-escalate potentially dangerous situations with mentally-ill individuals 
(Amador, 2012).   
Ideally, future research should focus on comparisons of self-reported versus 
independent assessments of LEAP fidelity as well as inclusion of client outcomes in 
assessing the effectiveness of LEAP interventions among various client populations. 
Future research should also assess how LEAP as an adjunctive intervention interacts with 
various therapy modalities in order to identify which psychotherapeutic modalities 
integrate ideally with this set of communication strategies. Also, research focusing on 
examining the various clinical and social contexts in which LEAP may be applicable will 











 In conclusion, this study focused on developing and evaluating the psychometric 
properties of a fidelity measure of clinicians’ adherence to a widely-used new clinical 
intervention known as LEAP and to assess and compare the fidelity ratings of clinicians 
who were trained in this approach versus those who were not.  The findings suggest that 
the LEAP Fidelity Measure is a reliable instrument that supports a three factor structure of 
principal components.  Furthermore, following a one-day training, clinicians assigned to 
the intervention group reported significantly higher fidelity to LEAP when compared to 
those who did not receive LEAP training. 
From a clinical perspective, anecdotal report from clinicians who were trained in 
LEAP supports the conclusion that this set of interventions appears to improve qualitative 
aspects of the therapeutic alliance.  Clinicians identified insight deficits as a significant 
clinical problem adversely affecting the therapeutic alliance and treatment engagement in 
this population and expressed a willingness to learn new interventions specifically 
addressing these particular challenges.  Moreover, the clinicians who participated in this 
study expressed a willingness to implement these techniques and to assess for themselves 
the effectiveness of LEAP interventions in not only improving client outcomes, but also in 
enhancing their own experiences of working with this challenging population.  As the 
positive and negative symptoms of schizophrenia and the associated impairments in global 
functioning often pose serious challenges in working with this population, interventions 





communication, and collaboration are paramount in affecting client outcomes and in 
preventing clinician burn-out.   
However, interventions meant for “real world” application can only be effective if 
dissemination and implementation of the approach is feasible and the complexities of the 
mental health service system are met with careful consideration.  Within this context, 
LEAP encompasses a set of adjunctive clinical interventions that can be easily 
disseminated and implemented in community mental health settings with minimal 
investment of time and resources.  By adding to the literature concerning the feasibility of 
training clinicians on new interventions that are widely used, the present study will 
contribute to the development of innovative, credible, and clinically-applicable 




























Aarons, G. A. (2004). Mental health provider attitudes toward adoption of evidence- 
based practice: The Evidence-Based Practice Attitude Scale (EBPAS). Mental 
Health Services Research, 6, 61–74.  
 
Aarons, G. A. (2005). Measuring provider attitudes toward evidence-based practice:  
Organizational context and individual differences. Child and Adolescent 
Psychiatric Clinics of North America, 14, 255–271.  
 
Aarons, G. A., Woodbridge, M., & Carmazzi, A. (2003). Examining leadership,  
organizational climate and service quality in a children’s system of care 
Proceedings of the 15th Annual Research Conference. A System of Care for 
Children’s Mental Health: Expanding the Research Base, Tampa, FL. 
 
Allness, D.J., & Knoedler, W.H. The PACT model of community-based treatment for  
Persons with severe and persistent mental illness: A manual for PACT start-up. 2nd 
ed. Arlington, VA: National Alliance for the Mentally Ill. 
 
Altamura, A. C., Bobes, J., Cunningham Owens, D., Gerlach, J., Hellewell, J., Kasper, S.,  
et al. (2000). Schizophrenia: Diagnosis and continuing treatment. Principles of 
practice from the European expert panel on the contemporary treatment of 
schizophrenia. International Journal of Psychiatry in Clinical Practice, 4, S1-S11. 
 
Amador, X. F. (2000). I am not sick, I don’t need help!: How to help someone with  
mental illness accept treatment. New York, NY: Vida Press. 
 
Amador, X. F. (2007). I am not sick, I don’t need help!: How to help someone with  
mental illness accept treatment (2nd ed.). New York, NY: Vida Press. 
 
Amador, X. F. (2010). I am not sick, I don’t need help!: How to help someone with  
mental illness accept treatment (10th Anniversary ed.). New York, NY: Vida Press. 
 
Amador, X. F. (2012). I am not sick, I don’t need help!: How to help someone with  
mental illness accept treatment (4th ed.). New York, NY: Vida Press. 
 
Amador, X. F. & David, A. S. (Eds.). (2004) Insight and Psychosis: Awareness of Illness  
In Schizophrenia and Related Disorders (2nd ed.). New York, NY: Oxford 
University Press. 
 
Amador, X. F., Flaum, M., Andreasen, N. C., Strauss, D. H., Yale, S. A., Clark, S. C., et al. 
(1994).  Awareness of illness in schizophrenia and schizoaffective and mood 






Amador, X. F., & Kronengold, H. (2004).  Understanding and assessing insight.  In X. 
Amador & A. David (Eds.), Insight and psychosis: Awareness of illness in 
schizophrenia and related disorders (2nd ed., pp. 3-30). New York, NY: Oxford 
University Press. 
 
Amador, X. F. & Paul-Odouard, R. (2000).  Defending the Unabomber: Anosognosia in 
schizophrenia. Psychiatric Quarterly, 71, 363 – 371. 
 
Amador, X. F., Strauss, D. H., Yale, S. A., & Gorman, J. M. (1991). Awareness of illness 
in schizophrenia. Schizophrenia Bulletin, 17, 113-32. 
 
American Psychiatric Association (2000). Diagnostic and statistical manual of mental 
disorders, 4th ed., Text Revision. Washington, DC: APA Press. 
 
Amminger, G. P., Pape, S., Rock, D., Roberts, S. A., Ott., S. L., Squires-Wheeler, E., et al. 
(1999). Relationship between childhood behavioral disturbances and later 
schizophrenia in the New York High-Risk project. American Journal of Psychiatry, 
156, 525-530. 
 
Arkowitz, H., & Miller, W. R. (2008). Learning, applying, and extending motivational 
interviewing. In H. Arkowitz, H. A. Westra, W. R. Miller, & S. Rollnick (Eds.), 
Motivational Interviewing: In the Treatment of Psychological Problems (pp. 1-25). 
New York, NY: Guilford Press. 
 
Atkinson, J. M., Coia, D. A., Gilmour, W. H., & Harper, J. P. (1996). The impact of  
education groups for people with schizophrenia on social functioning and quality of 
life. British Journal of Psychiatry, 168, 199-204. 
 
Ayuso-Gutiérrez, J. L., & del Rio Vega, J. M. (1997). Factors influencing relapse in the 
long-term course of schizophrenia. Schizophrenia Research, 28, 199-206. 
 
Baker, A. I., Lewin, T., Reichler, H., Clancy, R., Carr, V., Garrett, R., et al. (2002). 
 Motivational interviewing among psychiatric in-patients with substance use  
disorders.  Acta Psychiatrica Scandinavica, 106, 233-240. 
 
Barrowclough, C., Hadock, G., Tarrier, N., Lewis, S. W., Moring, J., O’Brien, R., et al.  
(2001). Randomized controlled trial of motivational interviewing, cognitive 
behavior therapy, and family intervention for patients with comorbid schizophrenia 
and substance use disorders. American Journal of Psychiatry, 158, 1706-1713. 
 
Bartko, G., Herczeg, I., & Zador, G. (1988). Clinical symptomatology and drug 
compliance in schizophrenic patients. Acta Psychiatrica Scandinavica, 77, 74-76. 
 
Baum, K. M. & Walker, E. F. (1995). Childhood behavioral precursors of adult symptoms 






Beidas, R. S., & Kendall, P. C. (2010). Training therapists in evidence-based practice: A  
critical review of studies from a systems-contextual perspective. Clinical 
Psychology: Science and Practice, 17, 1–30. 
 
Bellg, A., Borrelli, B., Resnick, B., Hecht, J., Minicucci, D. S., Ory, M., et al. (2004).  
Enhancing treatment fidelity in health behavior change studies: Best practices and 
recommendations from the Behavior Change Consortium. Health Psychology, 23, 
443–451. 
 
Beutler, L E., Machoado, P. P., & Neufeldt, S. (1994).  Therapist variables. In A.E.  
Bergin & S. L. Garfiled (Eds.), Handbook of psychotherapy and behavior change 
(4th ed., pp. 229-269). New York, NY: Wiley. 
 
Björkman, T. & Hansson, L. (2000). What do case managers do? An investigation of case 
manager interventions and their relationship to client outcome. Social Psychiatry 
and Psychiatric Epidemiology, 35, 43-50.  
 
Bond, G. R., Drake, R. E., Mueser, K. T., & Latimer, E. (2001).  Assertive community  
treatment for people with severe mental illness: Critical ingredients and impact on 
patients.  Disease Management and Health Outcomes, 9, 141-159. 
 
Bond, G. R., & Salyers, M. P. (2004). Prediction of outcome from the Dartmouth  
assertive community treatment fidelity scale. CNS Spectrums, 9, 937-942.  
 
Bordin, E. S. (1979). The generalizability of the psychoanalytic concept of the working 
alliance.  Psychotherapy: Theory, Research and Practice, 16, 252-260. 
 
Bordin, E. S. (1994). Theory and research on the therapeutic working alliance: New  
directions. In A. O. Horvath & L. S. Greenberg (Eds.), The Working Alliance: 
Theory, Research and Practice (pp. 13-37). New York: Wiley. 
 
Borrelli, B., Resnick, B., Bellg, A., Ogedegbe, G, Sepinwall, D., Orwig, D., et al. (2002,  
April). Enhancing treatment fidelity in health behavior change studies: Best 
practices and recommendations from the Behavioral Change Consortium. Seminar 
presented at the Annual Meeting of the Society of Behavioral Medicine, 
Washington, DC. 
 
Borrelli, B., Sepinwall, S., Ernst, D., Bellg, A., Czajkowski, S., Breger, R., et al. (2005). 
 A new tool to assess treatment fidelity and evaluation of treatment fidelity across  
10 years of health behavior research. Journal of Consulting and Clinical 
Psychology, 73, 852– 860.  
 
Bowman, D. G. (1993). Effects of therapist sex on the outcome of therapy.  
Psychotherapy, 30, 678-684. 
 





therapist sex on outcome of psychotherapy: A meta-analysis.  Psychotherapy, 38, 
142-148. 
 
Boyer, S. L., & Bond, G. R. (1999). Does assertive community treatment reduce burnout?  
A comparison with traditional case management. Mental Health Services Research, 
1, 31-45. 
 
Buchanan, A. (1992). A two-year prospective study of treatment compliance in patients 
with schizophrenia. Psychological Medicine, 22, 787-297. 
 
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., et 
al. (2010). The 2009 schizophrenia PORT psychopharmacological treatment 
recommendations and summary statements. Schizophrenia Bulletin, 36, 71-93. 
 
Burns, T., Catty, J., Dash, M., Roberts, C., Lockwood, A., & Marshall, M. (2007).  Use  
of intensive case management to reduce time in hospital in people with severe 
mental Illness: Systematic review and meta-regression. British Medical Journal, 
335, 336. 
 
Burns, B. J., & Santos, A. B. (1995). Assertive community treatment: An update of  
randomized trials.  Psychiatric Services, 46, 669-675. 
 
Bush, C. T., Langford, M. W., Rosen, P., & Gott, W. (1990). Operation outreach:  
Intensive case management for severely psychiatrically disabled adults. Hospital & 
Community Psychiatry, 41, 647-649. 
 
Bustillo, J., Lauriello, J., Horan, W., & Keith. S. (2001). The psychosocial treatment of 
schizophrenia: An update. American Journal of Psychiatry, 158, 163-167. 
 
Calsyn, R. J. (2000). A checklist for critiquing treatment fidelity studies. Mental Health  
Services Research, 2, 107-112. 
 
Carpenter, W. T., Bartko, J. J., Carpenter, C. L., & Strauss, J. S. (1976). Another view of 
schizophrenia subtypes. Archives of General Psychiatry, 33, 508-516.  
 
Carpenter, W. T., Hanlon, T. E., Heinrichs, D. W., Summerfelt, A. T., Kirkpatrick, B., 
Levine, J., et al. (1990). Continuous versus targeted medication in schizophrenic 
outpatients: Outcome results. American Journal of Psychiatry, 147, 1138-1148. 
 
Carroll, A., Fattah, S., Clyde, Z., Coffey, I., Owens, D. G. C., & Johnstone, E. C. (1999).  
Correlates of insight and insight change in schizophrenia. Schizophrenia Research, 
35, 247-253. 
 





al. (2006). Motivational interviewing to improve treatment engagement and 
outcome in individuals seeking treatment for substance abuse: A multisite 
effectiveness study. Drug and Alcohol Dependence, 81, 301–312. 
 
Carroll, K. M., Farentinos, C., Ball, S. A., Crits-Christoph, P., Libby, B., Morgenstern, J.,  
et al. (2002). MET meets the real world: Design issues and clinical strategies in the 
Clinical Trials Network. Journal of Substance Abuse Treatment, 23, 73– 80. 
 
Carroll, K. M., Martino, S., & Rounsaville, B. J. (2010). No train, no gain? Clinical  
Psychology: Science and Practice, 17, 36-40. 
 
Castro, F. G., Barrera, M. B., & Martinez, C. R. (2004). The cultural adaptation of  
prevention interventions: Resolving tensions between fidelity and fit. Prevention 
Science, 5, 41-45. 
 
Cernovsky, Z. Z., Landmark, J. A., Merskey, H., & Husni, M. (2004). Clinical correlates 
of insight in schizophrenia. Psychological Reports, 95, 821-827. 
 
Chadwick, N. B. (2001). The therapeutic alliance, awareness, and medication compliance 
in the treatment of schizophrenia. Dissertation Abstracts International: Section B: 
The Sciences and Engineering, 62, 158. 
 
Cohen, J. (1988). Statistical Power Analysis for the Behavioral Sciences (2nd ed.).  
Hillsdale, NJ: Lawrence Erlbaum Associates. 
 
Cohen, L., Sargent, M., & Sechrest, L. (1986). Use of psychotherapy research by 
professional psychologists. American Psychologist. 41, 198–206.  
 
Coldwell, C. M., & Bender, W. S. (2007). The effectiveness of assertive community 
treatment for homeless populations with severe mental illness: A meta-analysis. 
American Journal of Psychiatry, 164, 393-399. 
 
Consumer Reports. (1995, November). Mental health: Does therapy help? pp. 734-739. 
 
Corrigan, P. W., McCracken, S. G., & Holmes, E. P. (2001). Motivational interviews as  
goal assessment for persons with psychiatric disability. Community Mental Health 
Journal, 37, 113-122. 
 
Corriss, D. J., Smith, T. E., Hull, J. W., Lim, R. W., Pratt, S. I., & Romanelli, S. (1999). 
Interactive risk factors for treatment adherence in a chronic psychotic disorders 
population. Psychiatry Research, 89, 269-274. 
 
Couture, S. M., Roberts, D. L., Penn, D. L., Cather, C., Otto, M. W., & Goff, D. (2006). 
Do baseline client characteristics predict the therapeutic alliance in the treatment of 






Crits-Christoph, P., Baranackie, K., Kurcias, J.S., Beck, A.T., Carroll, K., Perry, K., et al.  
(1991). Meta-analysis of therapist effects in psychotherapy outcome studies.  
Psychotherapy Research, 1, 81-91. 
 
Crits-Christoph, P., & Mintz, J. (1991). Implications of therapist effects for the design  
and analysis of comparative studies of psychotherapy. Journal of Consulting and 
Clinical Psychology, 59, 20-26. 
 
Csernansky, J. G., & Schuchart, E. K. (2002). Relapse and rehospitalisation rates in  
patients with schizophrenia: Effects of second generation antipsychotics. CNS 
Drugs, 16, 473-484. 
 
Cuesta, M. J., Peralta, V., & Zarzuela, A. (2000). Reappraising insight in psychosis:  
Mutli-scale longitudinal study. British Journal of Psychiatry, 177, 233-240. 
 
Czajkowski, S. (2011). The importance of monitoring and maximizing treatment fidelity  
in public health research. Journal of Public Health Dentistry, 71, S67-S68. 
 
Davis, J. M., Chen, N. & Glick, I. D. (2003). A meta-analysis of the efficacy of second- 
generation antipsychotics. Archives of General Psychiatry, 60, 553-564. 
 
Day, E. A., Arthur, W., & Gettman, D. (2001). Knowledge structures and the acquisition  
of a complex skill. Journal of Applied Psychology, 86, 1022–1033. 
 
Dekker, J., Wijdenes, W., Koning, Y. A., Gardien, R., Hermandes-Willenborg, L., &  
Nusselder, H. (2002).  Assertive community treatment in Amsterdam. Community 
Mental Health Journal, 38, 425-434. 
 
Dickerson, F. B. (2000). Cognitive-behavioral psychotherapy for schizophrenia: A review 
of recent empirical studies. Schizophrenia Research, 43, 71-90. 
 
Dickerson, F. B., Boronow, J. J., Ringel, N. & Parente, F. (1997). Lack of insight among 
outpatients with schizophrenia. Psychiatric Services, 48, 195-199. 
 
Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., Goldberg, R. W.,  
et al. (2010). The 2009 schizophrenia PORT psychosocial treatment 
recommendations and summary statements. Schizophrenia Bulletin, 36, 48-70. 
 
Dolder, C. R., Lacro, J. P., Leckband, S., & Jeste, D. V. (2003). Interventions to improve 
antipsychotic medication adherence: Review of recent literature. Journal of 
Clinical Psychopharmacology, 23, 389-399. 
 
Drake, R. E., Goldman, H. H., Leff, H. S., Lehman, A. F., Dixon, L., Mueser, K. T., et al.  
(2001). Implementing evidence-based practices in routine mental health service 





Drury, V., Birchwood, M., & Cochrane, R. (2000). Cognitive therapy and recovery from 
acute psychosis: A controlled trial. Five-year follow-up. British Journal of 
Psychiatry, 177, 8-14. 
 
Eisenberg, N., & Lennon, R. (1983). Sex differences in empathy and related capacities.  
Psychological Bulletin, 94, 100–131. 
 
Essock., S. M., & Kontos, N. (1995). Implementing Assertive Community Treatment 
teams. Psychiatric Services, 46, 679-683. 
 
Eysenck, H. (1952). The effects of psychotherapy: An evaluation. Journal of Counseling   
Psychology, 16, 319-324. 
 
Farber, B. A. (2007). On the enduring and substantial influence of Carl Rogers’ not-quite  
necessary nor sufficient conditions.  Psychotherapy: Theory, Research, Practice, 
Training, 44, 289-294. 
 
Farber, B. A. & Lane, J. S. (2002). Positive regard. In J. C. Norcross (Ed.).  
Psychotherapy  relationships that work: Therapist contributions and 
responsiveness to patients (pp. 175–194). New York, NY: Oxford University Press. 
 
Farrington, D. P. (2003). Methodological quality standards for evaluation research.  
Annals of the American Academy of Political and Social Science, 587, 49-68. 
 
Fekete, D. M., Bond, G. R., McDonel, E. C., Salyers, M., Chen, A., & Miller, L. (1998).  
Rural assertive community treatment: A field experiment. Psychiatric 
Rehabilitation Journal, 21, 371-379. 
 
Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997). Determinants of medication 
compliance in schizophrenia: Empirical and clinical findings. Schizophrenia 
Bulletin, 23, 637-651. 
 
Fisher, E. H. (1989). Gender bias in therapy? An analysis of patient and therapist causal 
explanations. Psychotherapy, 26, 389-401. 
 
Flashman, L. A. (2004). Disorders of insight, self-awareness, and attribution in 
Schizophrenia. In B. D. Beitman and J. Nair (Eds.), Self-Awareness Deficits in 
Psychiatric Patients. New York, NY: W.W. Norton & Co. 
 
Ford, R., Beadsmore, A., Ryan, P., Repper, J., Craig, T., & Muijen, M. (1995). Providing  
the safety net: Case management for people with serious mental illness. Journal of 
Mental Health, 1, 91-97. 
 






Frank, A. F., & Gunderson, J. G. (1990). The role of the therapeutic alliance in the 
treatment of schizophrenia. Archives of General Psychiatry, 47, 228-236. 
 
Fraser, S. W., & Greenhalgh, T. (2001). Complexity science: Coping with complexity:  
Educating for capability. British Medical Journal, 323, 799–803. 
 
Freud, S. (1958). The dynamics of transference. In J. Starchy (Ed. & Trans.), The standard 
edition of the complete psychological works of Sigmund Freud (Vol. 12, pp. 99-
108). London, England: Hogarth Press. (Original work published 1912). 
 
Freud, S. (1958).  On the beginning of treatment: Further recommendations on the 
technique of psychoanalysis. In J. Starchy (Ed. & Trans.), The standard edition of 
the complete psychological works of Sigmund Freud (Vol. 12, pp. 122-144). 
London, England: Hogarth Press. (Original work published 1913). 
 
Freudenreich, O., Deckersbach, T., & Goff, D. C. (2004). Insight into current symptoms in 
schizophrenia: Association with frontal cortical function and affect. Acta 
Psychiatrica Scandinavica, 110, 14-20. 
 
Gaston, L. (1990). The concept of the alliance and its role in psychotherapy: Theoretical 
and empirical considerations. Psychotherapy, 27, 143-153. 
 
Gehrs, M., & Goering, P. (1994). The relationship between the working alliance and 
rehabilitation outcomes of schizophrenia. Psychosocial Rehabilitation Journal, 18, 
45-53. 
 
Gilligan, C. (1993). In a different voice: Psychological theory and women’s development.  
Cambridge, MA: Harvard University Press. 
 
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., et al. 
(2004). Adherence to treatment with antipsychotic medication and health care costs 
among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry, 
161, 692-699. 
 
Gould, R. A., Mueser, K. T., Bolton, M. A., Mays, V. K., & Goff, D. C. (2001). Cognitive 
therapy for psychosis in schizophrenia: An effect size analysis. Schizophrenia 
Research, 48, 335-342. 
 
Graeber, D. A., Moyers, T. B., Griffith, G., Guajardo, E., & Tonigan, S. (2003).  
Addiction services: A pilot study comparing motivational interviewing and an 
educational intervention in patients with schizophrenia and alcohol use disorders. 
Community Mental Health Journal, 39, 189-202. 
 
Gray, R. (2000). Does patient education enhance compliance with clozapine? A  






Gray, R., Leese, M., Bindman, J., Becker, T., Burti, L., David, A., et al. (2006). 
Adherence therapy for people with schizophrenia. European multicentre 
randomised controlled trial. British Journal of Psychiatry, 189, 508-514.  
 
Green, L. W., & Glasgow, R. E. (2006). Evaluating the relevance, generalization, and  
applicability of research: Issues in external validation and translation methodology. 
Evaluation and the Health Professions, 29, 126-153. 
 
Greenberg, R. N. (1984). Overview of patient compliance with medication dosing: A  
literature review. Clinical Therapeutics, 6, 592-599. 
 
Halford, W. K., & Hayes, R. L. (1995). Social skills in schizophrenia: Assessing the 
relationship between social skills, psychopathology, and community functioning. 
Social Psychiatry and Psychiatric Epidemiology, 30, 14-19. 
 
Hamernik, E., & Pakenham, K. I. (1999). Assertive community treatment for persons with 
severe mental disorders: A controlled treatment outcome study. Behavior Change, 
16, 259-268. 
 
Harrison, G., Hopper, K., Craig, T., Laska, E., Dube, K.C., Ganev, K., et al. (2001).  
Recovery from psychotic illness: A 15- and 25-year international follow-up study. 
British Journal of Psychiatry, 178, 506-517. 
 
Hasenfeld, Y. (Ed.). (1992). Human services as complex organizations Newbury Park,  
CA: Sage. 
 
Hatcher, S. L., Favorite, T. K., Hardy, E. A., Goode, R. L., Deshetler, R. A., & Thomas, R. 
M. (2005). An analogue study of therapist empathic process: Working with 
difference. Psychotherapy: Theory, Research, Practice, Training, 42, 198-210. 
 
Henggeler, S. W., & Schoenwald, S. K. (2002). Treatment manuals: Necessary, but far  
from sufficient. Clinical Psychology: Science and Practice, 9, 419–420. 
 
Henry, W. P., Strupp, H. H., Schacht, T. E., & Gaston, L. (1994). Psychodynamic 
approaches. In A. E. Bergin & S. L. Garfield (Eds.), Handbook of psychotherapy 
and behavior change (4th ed., pp. 467-508). New York, NY: Wiley. 
 
Hersoug, A. G., Monsen, J. T., Havik, O. E., & Hogeland, P. (2002). Quality of early 
working alliance in psychotherapy: Diagnoses, relationship and intrapsychic 
variables as predictors. Psychotherapy and Psychosomatics, 71, 18-27. 
 
Herz, M. I., Glazer, W. M., Mostert, M. A., Sheard, M. A., Szymanski, H. V., Hafez, H., et 
al. (1991). Intermittent vs. maintenance medication in schizophrenia: Two-year 
results. Archives of General Psychiatry, 48, 333-339. 
 





schizophrenia relapse and adjustment and the contributions of psychosocial 
treatment. Journal of Psychiatric Research, 32, 243–250. 
 
Hogue, A., Dauber, S., Chinchilla, P., Fried, A., Henderson, C., Inclan, J., et al. (2008).  
Assessing fidelity in individual and family therapy for adolescent substance abuse. 
Journal of Substance Abuse Treatment, 35, 137-147. 
 
Hohmann, A. A., & Shear, M. K. (2002). Community-based intervention research:  
Coping with the ‘‘noise’’ of real life in study design. American Journal of 
Psychiatry, 159, 201-207. 
 
Horvath, A. O. (1994). Research on the alliance. In A. O. Horvath & L. S. Greenberg 
(Eds.), The working alliance: Theory, research, and practice (pp. 259-286). New 
York, NY: Wiley. 
 
Horvath, A. O. (2000). The therapeutic relationship: From transference to alliance.  
Psychotherapy in Practice, 56, 163-173. 
 
Horvath, A. O., & Luborsky, L. (1993). The role of the therapeutic alliance in 
psychotherapy.  Journal of Consulting and Clinical Psychology, 61, 561-573. 
 
Horvath, A. O., & Symonds, B. D. (1991). Relation between working alliance and outcome 
in psychotherapy: A meta-analysis. Journal of Counseling Psychology, 38, 139-
149. 
 
Huppert, J. D., Bufka, L. F., Barlow, D. H., Gorman, J. K., Shear, M. K., & Woods, S. W. 
(2001). Therapists, therapist variables, and Cognitive-Behavioral Therapy outcome 
in a multicenter trial for Panic Disorder. Journal of Consulting and Clinical 
Psychology, 69, 747-755. 
 
Jankowicz, D. (2000). From “learning organization” to “adaptive organization.”  
Management Learning, 31, 471–490. 
 
Johnson, D. P., Penn, D. L., Bauer, D. J., Meyer, P., & Evans, E. (2007). Predictors of the 
therapeutic alliance in group therapy for individuals with treatment-resistant 
auditory hallucinations. British Journal of Clinical Psychology, 47, 171-183. 
 
Jordan, J. V. (1995). A relational approach to psychotherapy. Women and Therapy,  
16, 51–61. 
 
Jorgensen, P. (1995). Recovery and insight in schizophrenia. Acta Psychiatrica  
Scandinavica, 92, 436–440. 
 
Kasapis, C. (1996). Poor insight in schizophrenia: Neuropsychological and defensive 
aspects. Dissertation Abstracts International: Section B: The Sciences and 





Kazdin, A. (Ed.). (1997). The therapist as a neglected variable in psychotherapy research 
[Special section]. Clinical Psychology, Science and Practice, 59, 12-19. 
 
Keith, S. J., & Kane, J. M. (2003).  Partial compliance and patient consequences in 
schizophrenia: Our patients can do better. Journal of Clinical Psychiatry, 64, 1308 
– 1315. 
 
Kemp, R., & David, A. (1996). Psychological predictors of insight and compliance in 
psychotic patients. British Journal of Psychiatry, 169, 444-450. 
 
Kemp R., Hayward P., Applewhaite G., Everitt, B., & David, A. (1996) Compliance  
therapy in psychotic patients: Randomised controlled trial. British Medical Journal, 
312, 345–349. 
 
Kemp, R., Kirov, G., Everitt, B., Hayward, P., & David, A. (1998) Randomised  
controlled trial of compliance therapy: 18-month follow-up. British Journal of 
Psychiatry, 172, 413–419. 
 
Kernberg, O. F. (1976). Some methodological and strategic issues in psychotherapy  
research: Research implications of the Menninger Foundation psychotherapy 
research project. In R. L. Spitzer & D. F. Klein (Eds.), Evaluation of Psychological 
Therapies (pp. 23-38). Baltimore: John Hopkins University Press. 
 
Keshavan, M. S., Rabinowitz, J., DeSmedt, G., Harvey, P. D., & Schooler, N. (2004).  
Correlates of insight in first episode psychosis. Schizophrenia Research, 70, 187-
194. 
 
King, R., Le Bas, J., & Spooner, D. (2000). The impact of caseload on the personal  
efficacy of mental health case managers. Psychiatric Services, 51, 364-368.  
 
Kivlighan, D. M. (1998). Moderating effects of client attachment on the counselor 
experience-working alliance relationship. Journal of Counseling Psychology, 37, 
16-21. 
 
Kuipers, E., Fowler, D., Garety, P., Chisholm, D., Freeman, D., Dunn, G., et al., (1998). 
London-East Anglia randomized controlled trial of cognitive-behavioral therapy for 
psychosis, III: Follow-up and economic evaluation at 18 months. British Journal of 
Psychiatry, 173, 61-68. 
 
Lambert, M. J., & Bergin, A. E. (1994). The effectiveness of psychotherapy. In A. E. 
Bergin & S. L. Garfield (Eds.), Handbook of psychotherapy and behavior change 
(4th ed., pp. 143-189). New York, NY: Wiley. 
 
Larøi, F., Fannemel, M., Rønneberg, U., Flekkøy, K., Opjordsmoen, S., Dullerud, R., & 





relationship to structural brain measures and neuropsychological tests. Psychiatry 
Research: Neuroimaging, 100, 49-58. 
 
Leff, J., Thornicroft, G., Coxhead, N., & Crawford, C. (1994). The TAPS project. 22: A  
five-year follow-up of long-stay psychiatric patients discharged to the community. 
British Journal of Psychiatry Supplement, 25, 13-17. 
 
Lehman, A. F., Dixon, L. B., Hoch, J. S., DeForge, B., Kernan, E., & Frank, R. (1999). 
Cost-effectiveness of assertive community treatment for homeless persons with 
severe mental illness. British Journal of Psychiatry, 174, 346-352. 
 
Lehman, A. F., Dixon, L. B., Kernan, E., DeForge, B. R., & Postrado, L. T. (1997). A 
randomized trial of assertive community treatment for homeless persons with 
severe mental illness. Archives of General Psychiatry, 54, 1038-1043. 
 
Lennon, R., & Eisenberg, N. (1987). Gender and age differences in empathy and  
sympathy. In N. Eisenberg & J. Strayer (Eds.), Empathy and its development (pp. 
195–217). New York, NY: Cambridge University Press. 
 
Levy, S. T., McGlashan, T. H., & Carpenter, W. T. (1975). Integration and sealing over as 
recovery styles from acute psychosis. Journal of Nervous and Mental Disease, 16, 
307-312. 
 
Luborsky, L., Auerbach, A. H., Chander, M., Cohen, J., & Bachrach, H. (1971). Factors 
influencing the outcome of psychotherapy: A review of quantitative research. 
Psychological Bulletin, 75, 145-185. 
 
Macdonald, E.M., Jackson, H.J., Hayes, R.L., Baglioni, A.J., & Madden, C. (1998). Social 
skills as a determinant of social networks and perceived social support in 
schizophrenia.  Schizophrenia Research, 29, 275-286. 
 
Marshall, M., & Lockwood, A. (2010). Assertive community treatment for people with  
severe mental disorders. Cochrane Database of Systematic Reviews. 
 
Marshall, M., Lockwood, A., & Green, R. (2010). Case management for people with  
severe mental disorders. Cochrane Database of Systematic Reviews. 
 
Martin, D. J., Garske, J. P., & Davis, M. K. (2000). Relation of the therapeutic alliance 
with outcome and other variables: A meta-analytic review. Journal of Consulting 
and Clinical Psychology, 68, 438-450. 
 
Masand, P. S. & Narasimhan, M. (2006). Improving adherence to antipsychotic 
pharmacotherapy. Current Clinical Pharmacology, 1, 47-56. 
 





adherence in individuals with schizophrenia. In H. Arkowitz, H. A. Westra, W. R. 
Miller, & S. Rollnick (Eds.), Motivational Interviewing: In the Treatment of  
Psychological  Problems (pp. 249-276). New York, NY: Guilford Press. 
 
McEvoy, J. P. (2004).  The relationship between insight into psychosis and compliance 
with medications.  In X. Amador & A. David (Eds.), Insight and psychosis: 
Awareness of illness in schizophrenia and related disorders (2nd ed., pp. 311-333). 
New York, NY: Oxford University Press. 
 
McEvoy, J. P., Appelbaum, P. S., Apperson, L. J., Geller, J. L., & Freter, S. (1989). Why 
must some schizophrenic patients be involuntarily committed? The role of insight. 
Comprehensive Psychiatry, 30, 13-17. 
 
McEvoy, J. P., Freter, S., Everett, G., Geller, J. L., Appelbaum, P., Apperson, L. J., et al. 
(1993). Insight and the clinical outcome of schizophrenic patients. Journal of 
Nervous and Mental Disease, 177, 48-51. 
 
McGrew, J. H., & Bond, G. R. (1995). Critical ingredients of assertive community  
treatment: Judgments of the experts. Journal of Mental Health Administration, 22, 
113-125. 
 
Miller, W. R., & Rollnick, S. (1991). Motivational interviewing: Preparing people to  
change addictive behavior. New York, NY: Guilford Press.  
 
Miller, W. R., & Rollnick, S. (2002). Motivational Interviewing: Preparing people for  
change (2nd ed.). New York, NY: Guilford Press. 
 
Mitchell, K. M., Bozart, J. D., & Krauft, C. C. (1977). Reappraisal of the therapeutic  
effectiveness of accurate empathy, non-possessive warmth, and genuineness.  In  
A. S. Gurman & A. M. Razin (Eds.), Effective Psychotherapy (pp. 482-502). New 
York, NY: Pergamon Press. 
 
Misdrahi, D., Petit, M., Blanc, O., Bayle, F., & Llorca, P. M. (2012). The influence of  
therapeutic alliance and insight on medication adherence in schizophrenia. Nordic 
Journal of Psychiatry, 66, 49-54. 
 
Moncher, F. J., & Prinz, R. J. (1991). Treatment fidelity in outcome studies. Clinical  
Psychology Review, 11, 247-266. 
 
Morgan, K. D., & David, A. S. (2004).  Neuropsychological studies of insight in patients 
with psychotic disorders. In X. Amador & A. David (Eds.), Insight and psychosis: 
Awareness of illness in schizophrenia and related disorders (2nd ed., pp. 177-193). 






Morse, G. A., Calsyn, R. J., Allen, G., Tempelhoff, B., & Smith, R. (1992). Experimental 
comparison of the effects of three treatment programs for homeless mentally ill 
people.  Hospital & Community Psychiatry, 43, 1005-1010. 
 
Morse, G. A., Calsyn, R. J., Klinkenberg, W. D., Helminiak, T. W., Wolff, N., Drake, R. 
E., et al. (2006). Treating homeless clients with severe mental illness and substance 
abuse disorders: Costs and outcomes. Community Mental Health Journal, 42, 377-
404. 
 
Morse, G. A., Calsyn, R. J., Klinkenberg, W. D., Trusty, M. L., Gerber, F., Smith, R., et al. 
(1997). An experimental comparison of three types of case management for 
homeless mentally ill people. Psychiatric Services, 48, 497-503. 
 
Mowbray, C. T., Holter, M. C., Teague, G. B., & Bybee, D. (2003). Fidelity criteria:  
Development, measurement, and validation. American Journal of Evaluation, 24, 
315-340. 
 
Mueser, K. T., Bellack, A. S., Douglas, M. S., & Morrison, R. L. (1991). Prevalence and 
stability of social skills deficits in schizophrenia. Schizophrenia Research, 5, 167-
176. 
 
Naleppa, M. & Cagle, J. (2010). Treatment fidelity in social work intervention research:  
A review of published studies. Research on Social Work Practice, 20, 674-681. 
 
Nathan, P. E., Stuart, S. P., & Dolan, S. L. (2000).  Research on psychotherapy efficacy 
and effectiveness: Between Scylla and Charybdis?  Psychological Bulletin, 126, 
964-981. 
 
Neale, M. S., & Rosenheck, R. A. (1995). Therapeutic alliance and outcome in a VA 
intensive case management program. Psychiatric Services, 46, 719-721. 
 
Nelson, E. A. (1997). “Poor insight” as a manifestation of psychological defensiveness in 
schizophrenia. Dissertation Abstracts International: Section B: The Sciences and 
Engineering, 58, 2132. 
 
Nelson, G., Aubry, T., & Lafrance, A. (2007). A review of the literature on the 
effectiveness of housing and support, assertive community treatment, and intensive 
case management interventions for persons with mental illness who have been 
homeless. American Journal of Orthopsychiatry, 77, 350-361. 
 
Nosé, M., Barbui, C., Gray, R.. & Tansella, M. (2003). Clinical interventions for  
treatment non-adherence in psychosis: Meta-analysis. British Journal of 
Psychiatry, 183, 197-206. 
 





(2003). Compliance therapy: A randomised controlled trial in schizophrenia. 
British Medical Journal, 327, 834.  
 
Oehl, M., Hummer, M., & Fleischhacker, W. W. (2000). Compliance with antipsychotic 
treatment. Acta Psychiatrica Scandanavica, 102, 83-86. 
 
Olfson, M., Glick, I., & Mechanic, D. (1993). Inpatient treatment of schizophrenia in 
general hospitals. Hospital and Community Psychiatry, 44, 40-44. 
 
Olfson, M., Mechanic, D., Hansell, S., Boyer, C. A., Walkup, J., & Weiden, P. (2000). 
Predicting medication non-compliance after hospital discharge among patients with 
schizophrenia.  Psychiatric Services, 51, 216-222.  
 
Safran, J. D., Goldfried, M. R., & Muran, J. C. (Eds.). (1995). The therapeutic alliance. In 
Session: Psychotherapy in Practice, 1, 1-92.  
 
Shapiro, D. A. & Shapiro, D. (1983). Comparative therapy outcome research:  
Methodological implications of meta-analysis. Journal of Consulting and Clinical 
Psychology, 51, 42-53. 
 
Simpson, D. D. (2002). A conceptual framework for transferring research to practice.  
Journal of Substance Abuse Treatment, 22, 171–182 
 
Paillot, C., Goetz, R., & Amador, X. F. (2009). Double blind, randomized, controlled  
study of a psychotherapy designed to improve motivation for change, insight into 
schizophrenia and adherence to medication. Schizophrenia Bulletin, 35, 343. 
 
Parkes, C. M., Brown, G. W., & Monck, E. M. (1982). The general practitioner and the 
schizophrenic patient. British Medical Journal, 1, 972-976. 
 
Penn, D. L., Mueser, K. T., Tarrier, N., Gloege, A., Cather, C., Serrano, D., et al. 
(2004). Supportive therapy for schizophrenia: Possible mechanisms and 
implications for adjunctive psychosocial treatments. Schizophrenia Bulletin, 30, 
101-112. 
 
Perepletchikova, F., & Kazdin, A. (2005). Treatment integrity and therapeutic change:  
Issues and research recommendations. Clinical Psychology: Science and Practice, 
12, 365-383. 
 
Persons, R., Persons, M., & Newmark, I. (1974). Perceived helpful therapists’  
characteristics, client improvements, and sex of therapist and client. 
Psychotherapy: Theory, Research, and Practice, 11, 63-65. 
 
Phillips, S. D., Burns, B. J., Edgar, E. R., Mueser, K. T., Linkins, K. W., Rosenheck,  
R.A., et al. (2001).  Moving assertive community treatment into standard  practice. 






Pini, S., Cassano, G. B., Dell’Osso, L., & Amador, X. F. (2001). Insight into illness in 
schizophrenia, schizoaffective disorder, and mood disorders with psychotic 
features.  American Journal of Psychiatry, 158, 122-125. 
 
Prigatano, G. P. & Schacter, D. L. (Eds.). (1991).  Awareness of deficit after brain injury: 
Clinical and theoretical issues. New York, NY: Oxford University Press. 
 
Prince, J. D. (2007). Therapeutic alliance, illness awareness, and number of 
hospitalizations for schizophrenia. The Journal of Nervous and Mental Disease, 
195, 170-174. 
 
Prochaska, J. O., DiClemente, C. C., & Norcross, J. C. (1992). In search of how people  
change: Applications to addictive behaviors. American Psychologist, 47, 1102-
1114. 
 
Ratakonda, S., Gorman, J. M., Yale, S. A., & Amador, X. F. (1998). Characterization of 
psychotic conditions. Archives of General Psychiatry, 55, 75-82. 
 
Rathod, S., Kingdon, D., Smith, P., & Turkington, D. (2005). Insight into schizophrenia:  
The effects of cognitive behavioural therapy on the components of insight and 
association with sociodemographics - data on a previously published randomised 
control trial. Schizophrenia Research, 74, 211-219. 
 
Rentsch, J. R., & Klimoski, R. J. (2001). Why do ‘great minds’ think alike? Antecedents  
of team member schema agreement. Journal of Organizational Behavior, 22, 107–
120. 
 
Rogers, C.R. (1957). The necessary and sufficient conditions of therapeutic personality  
change. Journal of Counseling Psychology, 21, 95-103. 
 
Rogers, C., & Dymond, R. (1954). Psychotherapy and personality change. Chicago, IL: 
 University of Chicago Press. 
 
Rogers, C., & Wood, J.K. (1974). Client-centered therapy: Carl R. Rogers. In A. Burton 
(Ed.), Operational theories of personality (pp. 237-254). New York, NY: 
Brunner/Mazel. 
 
Rosen, A. M., Mukherjee, S., Olarte, S., Varia, V., & Cardenas, C. (1982). Perception of 
tardive dyskinesia in outpatients receiving maintenance neuroleptics. American 
Journal of Psychiatry, 139, 372-373. 
 
Rosenheck, R. A., & Neale, M. S. (1998). Cost-effectiveness of intensive psychiatric 
community care for high users of inpatient services. Archives of General 






Rüsch, N. & Corrigan, P. W. (2002). Motivational interviewing to improve insight and  
treatment adherence in schizophrenia. Psychiatric Rehabilitation Journal, 26, 23-
32. 
 
Sands, R. G. & Cnann, R. A. (1994). Two models of case management: Assessing their  
impact. Community Mental Health Journal, 30, 441-457. 
 
Saunders, S. M. (2001). Pretreatment correlates of the therapeutic bond. Journal of 
Clinical Psychology, 57, 1339-1352. 
 
Schmand, B., Kuipers, T., Van Der Gaag, M., Bosveld, J., Bulthuis, F., & Jullema, A.  
(1994). Cognitive disorders and negative symptoms as correlates of motivational 
deficits in psychotic patients. Psychological Medicine, 24, 869-884. 
 
Schooler, N. R., Keith, S. J., Severe, J. B., Matthews, S. M., Bellack, A. S., Glick, I. D., et 
al. (1997). Relapse and rehospitalization during maintenance treatment of 
schizophrenia: The effects of dose reduction and family treatment. Archives of 
General Psychiatry, 54, 453-463. 
 
Scott, J. E., & Dixon, L. B. (1995). Assertive community treatment and case management 
for schizophrenia. Schizophrenia Bulletin, 21, 657-668. 
 
Semrad, E. V. (1966). Long term therapy of schizophrenia. In G. Usdin (Ed.), 
Psychoneuroses and Schizophrenia. Philadelphia, PA: J. B. Lippincott. 
 
Sensky, T., Turkington, D., Kingdon, D., Scott, J. L., Scot, J., Siddle, R., et al. (2000). A 
randomized control trial of cognitive-behavioral therapy for persistent symptoms in 
schizophrenia resistant to medication. Archives of General Psychiatry, 57, 165-172. 
 
Sexton, T. L., & Whiston, S. C. (1991). A review of the empirical basis for counseling: 
Implications for practice and training. Counselor Education and Supervision, 30, 
330-354. 
 
Sevy, S., Nathanson, K., Visweswaraiah, H., & Amador, X. (2004). The relationship 
between insight and symptoms in schizophrenia. Comprehensive Psychiatry, 45, 
16-19.  
 
Shad, M. U., Muddasani, S., Prasad, K., Sweeney, J. A., & Keshavan, M. S. (2004).  
Insight and prefrontal cortex in first-episode schizophrenia. Neuroimage, 22, 1315-
1320. 
 
Sharma, T. & Antanova, L. (2003). Cognitive function in schizophrenia. Deficits,  
functional consequences, and future treatment. Psychiatric Clinics of North 
America, 26, 25-40. 
 





about their illness: The effect of residual symptoms.  Journal of Mental Health, 1, 
61-70. 
 
Smith, M. L., Glass, G. V., & Miller, T. I. (1980). The benefits of psychotherapy.  
Baltimore, MD: Johns Hopkins University Press. 
 
Smith, T. E., Hull, J. W., Goodman, M., Hedeyat-Harris, A., Wilson, D. G., Israel, L. M., 
et al. (1999). The relative influence of symptoms, insight, and neurocognition on 
social adjustment in schizophrenia and schizoaffective disorder. Journal of Nervous 
and Mental Disease, 187, 102-108. 
 
Solomon, P., Draine, J., & Delaney, M. (1995). The working alliance and consumer case 
management. The Journal of Mental Health Administration, 22, 126-134. 
 
Stein, D. M., & Lambert, M. (1995). Graduate training in psychotherapy: Are therapy  
outcomes enhanced? Journal of Consulting and Clinical Psychology, 63, 182-196. 
 
Stein, L. I., & Test, M. A. (1980). Alternative to mental hospital treatment. I. Conceptual  
model, treatment program, and clinical evaluation. Archives of General Psychiatry, 
37, 392-397. 
 
Stricker, G., & Gold, J. R. (1996). Psychotherapy integration: An assimilative,  
psychodynamic approach. Clinical Psychology: Science and Practice, 3, 47–58. 
 
Sullivan, G., Wells, K.B., Morgenstern, H., & Leake, B. (1995). Identifying modifiable 
risk factors for rehospitalization: A case-control study of seriously mentally ill 
persons in Mississippi. American Journal of Psychiatry, 152, 1749-1756. 
 
Surgeon General. Surgeon General’s Report on Mental Health. Washington, DC: U.S. 
Government Printing Office. 
 
Svarstad, B. L., Shireman, T. I., & Sweeney, J. K. (2001). Using drug claims data to assess 
the relationship of medication adherence with hospitalization and costs. Psychiatric 
Services, 52, 805-811. 
 
Svensson, B., & Hansson, L. (1999a). Therapeutic alliance in cognitive therapy for 
schizophrenic and other long-term mentally ill patients: Development and 
relationship to outcome in an in-patient treatment programme. Acta Psychiatrica 
Scandinavica, 99, 281-287. 
 
Swanson, A. J., Pantalon, M. V., & Cohen, K. R. (1999). Motivational interviewing and  
treatment adherence among psychiatric and dually diagnosed patients. Journal of 






Sytema, S., Wunderink, L., Bloemers, W., Roorda, L., & Wiersma, D. (2007). Assertive 
community treatment in the Netherlands: A randomized controlled trial. Acta 
Psychiatric Scandinavica, 116, 105-112. 
 
Tamminga, C. A. & Schulz, S. C. (Eds.). (1991). Advances in neuropsychiatry and 
psychopharmacology: Volume 1. Schizophrenia research. New York, NY: Raven 
Press. 
 
Tarrier, N., Beckett, R., Harwood, S., Baker, A., Yusupoff, L., & Ugarteburu, I. (1993). A 
trial of two cognitive-behavioral methods of drug-resistant psychotic symptoms in 
schizophrenia. British Journal of Psychiatry, 162, 524-532. 
 
Tarrier, N., Wittkowski, A., Kinney, C., McCarthy, E., Morris, J., & Humphreys, J. (1999). 
Durability of the effects of cognitive-behavioral therapy in the treatment of 
schizophrenia: 12 month follow-up. British Journal of Psychiatry, 174, 500-504. 
 
Tattan, T., & Tarrier, N. (2000). The expressed emotion of case managers of the seriously 
mentally ill: The influence of expressed emotion on clinical outcomes. 
Psychological Medicine, 30, 195-204. 
 
Teschinsky, U. (2000). Living with schizophrenia: The family illness experience. Issues in 
Mental Health Nursing, 21, 387-396. 
 
Tremeau, F., Amador, X. F., Malaspina, D., Amodt, L., Goetz, R., & Gorman, J. (1997). 
Insight and anosognosia of tardive dyskinesia in schizophrenia. Schizophrenia 
Research, 24, 273. 
 
VandenBos, G. R. (1980). Psychotherapy: Practice, research, policy. Beverly Hills, CA:  
Sage. 
 
Van Putten, T., Crumptom, E., & Yale, C. (1976). Drug refusal in schizophrenia and the 
wish to be crazy. Archives of General Psychiatry, 33, 1443-1446. 
 
Velligan, D., Diamond, P. M., Mintz, J., Maples, N., Li, X., Zeber, J., et al. (2008). 
The use of individually tailored environmental supports to improve medication 
adherence and outcomes in schizophrenia. Schizophrenia Bulletin, 34, 483-493. 
 
Velligan, D. I., Lam, F., Ereshefsky, L., & Miller, A. L. (2003). Psychopharmacology: 
Perspectives on medication adherence and atypical antipsychotic medications. 
Psychiatric Services, 54, 665-667. 
 
Velligan, D. I, Lam, Y. F., Glahn, D. C., Barrett, J. A., Maples, N. J., Ereshefsky, L., et al. 
(2006). Defining and assessing adherence to oral antipsychotics: A review of the 






Vermilyea, B. B., Barlow, D. H., & O’Brien, G. T. (1984). The importance of assessing 
 treatment integrity: An example in the anxiety disorders. Journal of Behavioral 
 Assessment, 6, 1–11. 
 
Vocisano, C., Klein, D. N., Arnow, B., Rivera, C., Blalock, J. A., Rothbaum, B., et al. 
(2004). Therapist variables that predict symptom change in psychotherapy with 
chronically depressed patients.  Psychotherapy: Theory, Research, Practice, 
Training, 41, 255-265.  
 
Wampold, B. E., Imel, Z. E., Bhati, K. S., & Johnson-Jennings, M. D. (2007). Insight as a  
common factor. In L. G. Castonguay & C. Hill (Eds.), Insight in psychotherapy 
(pp. 119-139). Washington, DC: American Psychological Association. 
 
Watson, J. C. (2007). Reassessing Rogers’ necessary and sufficient conditions of change.  
Psychotherapy: Theory, Research, Practice, Training, 44, 268-273. 
 
Weiden, P. J., Dizon, L., Frances, A., Appelbaum, P., Haas, G., & Rapkin, B. (1991). 
Neuroleptic noncompliance in schizophrenia. In C. A. Tamminga & S. C. Schulz 
(Eds.), Advances in neuropsychiatry and psychopharmacology (pp. 285-296). New 
York, NY: Raven Press. 
 
Weiden, P., & Glazer, W. (1997) Assessment and treatment selection for "revolving  
door" inpatients with schizophrenia. Psychiatric Quarterly, 68, 377-392. 
 
Weiden, P. J., Rapkin, B., Zygmunt, A., Mott, T., Goldman, D., & Frances, A.  (1995). 
Post-discharge medication compliance of inpatients converted from an oral to a 
depot neuroleptic regimen. Psychiatric Services, 46, 1049-1054. 
 
Wilson, W. H., Ban, T. A., & Guy, W. (1986). Flexible system criteria in chronic 
schizophrenia.  Comprehensive Psychiatry, 27, 259-265. 
 
Wittorf, A., Jakobi, U., Bechdolf, A., Muller, B., Sartory, G., Wagner, M., et al. (2009). 
The influence of baseline symptoms and insight on the therapeutic alliance early in 
the treatment of schizophrenia. European Psychiatry, 24, 259-267. 
 
Wolff, N., Helminiak, T. W., Morse, G. A., Calsyn, R. J., Klinkenberg, W. D., & Trusty, 
M. L. (1997). Cost-effectiveness evaluation of three approaches to case 
management for homeless mentally ill clients. American Journal of Psychiatry, 
154, 341-348. 
 
World Health Organization (1973). Report of the International Pilot Study of 
Schizophrenia. Geneva, Switzerland: WHO Press. 
 
Wyatt R. J,, Henter, I., Leary, M.C., & Taylor, E. (1995). An economic evaluation of 







Yeaton, W., & Sechrest, L. (1981). Critical dimensions in the choice and maintenance of  
successful treatments: Strength, integrity, and effectiveness. Journal of Consulting 
and Clinical Psychology, 49, 156–167. 
 
Young, D. A., Davila, R., & Scher, H. (1993). Unawareness of illness and 
neuropsychological performance in chronic schizophrenia. Schizophrenia 
Research, 10, 117-124. 
 
Young, J. L, Zonana, H. V., & Shepler, L. (1986). Medication noncompliance in  
schizophrenia: Codification and update. Bulletin of the American Academy of 
Psychiatry & Law, 14, 105-122. 
 
Ziguras, S. J., & Stuart, G. W. (2000). A meta-analysis of the effectiveness of mental  
health case management over 20 years.  Psychiatric Services, 51, 1410-1421. 
 
Zlotnick, C., Elkin, I., & Shea, T. M. (1998). Does the gender of a patient or the gender  
of a therapist affect the treatment of patients with major depression? Journal of 
Consulting and Clinical Psychology, 66, 655-659. 
 
Zygmunt, A., Olfson, M., Boyer, C. A., & Mechanic, D. (2002). Interventions to improve 




























APPENDIX A: Recruitment Letter 
 
Date: 12/06/2011 
To: ACT clinicians 
 
You are being asked to participate in a pilot fidelity study of the Listen-Empathize-Agree-
Partner (LEAP) approach to communicating with clients.  LEAP is a communication 
intervention that incorporates components of motivational enhancement, client-centered, 
and cognitive therapies with the primary focus of strengthening the therapeutic alliance and 
improving treatment adherence. LEAP emphasizes the importance of strengthening the 
therapeutic alliance with the objective of optimizing respectful and non-judgmental 
communication with the client. The ultimate goal of LEAP is to develop a trusting and 
accepting environment that enables the practitioner to become more persuasive in his or 
her treatment recommendations to the client.  We believe that implementation of LEAP 
interventions with ACT consumers will (1) improve treatment adherence, (2) improve 
service engagement, and (3) reduce the risk for repeated psychiatric crises.     
 
If you decide to participate in the study, you will be assigned to either the control or 
intervention group.  For intervention group clinicians, you will be trained in LEAP by Dr. 
Xavier Amador, the developer of the intervention. LEAP training and certification will be 
offered at no cost (tuition of $750 will be waived) and you will be provided a copy of Dr. 
Amador’s book I am not sick I don’t need help! (Amador, 2010).  Following training, you 
will be asked to employ LEAP interventions with ACT consumers during your regular 
interactions and 6 weeks following training, you will be asked to complete a brief LEAP 
fidelity interview via telephone.   
 
For ACT clinicians assigned to the control group, you will asked to complete a brief LEAP 
fidelity interview via telephone within 6 weeks after you agree to participate in the study.  
After you complete the interview, your team will be trained in LEAP by Dr. Xavier 
Amador and LEAP training and certification will be offered at no cost.  You will also be 
provided a copy of Dr. Amador’s book I am not sick I don’t need help! (Amador, 2010).   
 
The principal investigator of this study, Mia Ihm, M.Phil., will be contacting you in two 
weeks to ask if you would like to participate.  You can also contact her at 646-775-8736 or 
mai2105@columbia.edu  should you have any questions or comments; or if you decide 
that you would prefer not to contacted regarding the study. 
 
Your decision to participate or not to participate will not affect your employment status. 
 
Thank you for your consideration, 
 
Mia A. Ihm, M.Phil., Principal Investigator 
Xavier Amador, Ph.D., Co-Investigator 







APPENDIX B: Informed Consent Form 
 
December 6, 2011 
INFORMED CONSENT 
DESCRIPTION OF THE RESEARCH: You are being asked to participate in a pilot 
fidelity study of the Listen-Empathize-Agree-Partner (LEAP) approach to communicating 
with clients.  LEAP is a communication intervention that incorporates components of 
motivational enhancement, client-centered, and cognitive therapies with the primary focus 
of strengthening the therapeutic alliance and improving treatment adherence. LEAP 
emphasizes the importance of strengthening the therapeutic alliance with the objective of 
optimizing respectful and non-judgmental communication with the client. The ultimate 
goal of LEAP is to develop a trusting and accepting environment that enables the 
practitioner to become more persuasive in his or her treatment recommendations to the 
client.  We believe that implementation of LEAP interventions with ACT consumers will 
(1) improve treatment adherence, (2) improve service engagement, and (3) reduce the risk 
for repeated psychiatric crises.     
 
The alternative to taking part in this study would be to continue with your regular job 
duties without participating in the LEAP training, implementation, and fidelity interview. 
 
If you agree to participate in the study, you will be randomly assigned to either the control 
group or the intervention group.  For the intervention group, the principal investigators, 
Mia Ihm and Dr. Amador, will provide LEAP training and certification at no cost (tuition 
of $750 will be waived) at an ACT office.  You will be provided a copy of Dr. Amador’s 
book I am not sick, I don’t need help! (Amador, 2010) and will be asked to read the book 
prior to the training seminar.  The training will last approximately 5 hours and lunch will 
be provided.   
 
Following the training, you will be asked to employ LEAP interventions and strategies 
with ACT consumers during your normal clinical interactions. Six weeks after training, 
you will be asked to participate in a brief telephone interview that will involve an 
assessment of your fidelity to LEAP principles.  The interview will last approximately 20-
30 minutes. 
 
For ACT clinicians assigned to the control group, you will be asked to complete the LEAP 
Fidelity Interview prior to receiving LEAP training.  You will receive LEAP training and 
certification at no cost within 6 weeks after giving informed consent to participate in the 
study at an ACT office.  You will be provided a copy of Dr. Amador’s book I am not sick, 
I don’t need help! (Amador, 2010) and will be asked to read the book prior to the training 
seminar.  The training will last approximately 5 hours and lunch will be provided.   
 
RISKS AND BENEFITS: We anticipate minimal risk of injury due to participation.  
Although you may be concerned about how participation in this study may influence your 





In addition, should you decide to participate, your responses will also have no bearing on 
your employment.  We anticipate that you may receive some professional benefits due to 
participation. You may professionally benefit as the LEAP training may assist in your 
clinical practice with Severe and Persistent Mentally Ill (SPMI) consumers. 
PAYMENTS: LEAP training and certification will be provided at no cost to you (tuition of 
$750 will be waived).  In addition, you will be provided a copy of Dr. Amador’s book I am 
not sick I don’t need help! (Amador, 2010) at no cost. 
DATA STORAGE TO PROTECT CONFIDENTIALITY: No identifying information will 
be entered electronically.  Rather, a numerical code will be used to link electronic and 
paper records. Consequently, no one but the Principal Investigator will have access to the 
personal identities of study participants. 
 
All study documents (consent form, notes, interview responses) will be stored in locked 
files in the Principal Investigator’s office and will be kept confidential to the extent 
permitted by law.   Electronic data will be kept on a password protected drive accessible 
only to Mia Ihm. 
 
Study documents will only be available to research staff, and State and Institutional 
regulatory personnel who may review documents as part of routine audits. 
TIME INVOLVEMENT: Your participation in the LEAP training will take approximately 
5 hours. For intervention group ACT clinicians, you will be asked to practice the LEAP 
method twice with each consumer on your caseload for 6 weeks following the training.  
There is no minimum or maximum time implied for each encounter. In addition, the LEAP 
Fidelity Measure will take approximately 20-30 minutes to complete.   
For control group ACT clinicians, your participation in the LEAP training will take 
approximately 5 hours.  In addition, the LEAP Fidelity Measure will take approximately 
20-30 minutes to complete. 
HOW WILL RESULTS BE USED: The results of the study will be used for the Principal 
Investigator’s dissertation and may be published in professional journals.  Furthermore, 
overall results will be presented to ACT and the Office of Mental Health regarding further 











Principal Investigator: ____Mia Ihm, M.Phil.__________________________________ 
Research Title: A Pilot Fidelity Study of Listen-Empathize-Agree-Partner (LEAP) with 
Assertive Community Treatment (ACT) Mental Health Clinicians 
 I have read and discussed the Research Description with the researcher. I have had 
the opportunity to ask questions about the purposes and procedures regarding this 
study.  
 My participation in research is voluntary. I may refuse to participate or withdraw 
from participation at any time without jeopardy to future medical care, 
employment, student status or other entitlements.  
 The researcher may withdraw me from the research at his/her professional 
discretion.  
 If, during the course of the study, significant new information that has been 
developed becomes available which may relate to my willingness to continue to 
participate, the investigator will provide this information to me.  
 Any information derived from the research project that personally identifies me 
will not be voluntarily released or disclosed without my separate consent, except as 
specifically required by law.  
 If at any time I have any questions regarding the research or my participation, I can 
contact the investigator, who will answer my questions. The investigator's phone 
number is (646) 775-8736.  
 If at any time I have comments, or concerns regarding the conduct of the research 
or questions about my rights as a research subject, I should contact the Teachers 
College, Columbia University Institutional Review Board /IRB. The phone number 
for the IRB is (212) 678-4105. Or, I can write to the IRB at Teachers College, 
Columbia University, 525 W. 120th Street, New York, NY, 10027, Box 151.  
 I should receive a copy of the Research Description and this Participant's Rights 
document.  
 If video and/or audio taping is part of this research, I ( ) consent to be audio/video 
taped. I ( ) do NOT consent to being video/audio taped. The written, video and/or 
audio taped materials will be viewed only by the principal investigator and 
members of the research team.  
 Written, video and/or audio taped materials ( ) may be viewed in an educational 
setting outside the research, or  
( ) may NOT be viewed in an educational setting outside the research. 






Participant's signature: ________________________________ Date:____/____/____ 
Name: ________________________________ 
 
Investigator's Verification of Explanation 
I certify that I have carefully explained the purpose and nature of this research to 
_________________________ (participant’s name) in age-appropriate language. He/She 
has had the opportunity to discuss it with me in detail. I have answered all his/her 
questions and he/she provided the affirmative agreement (i.e. assent) to participate in this 
research. 











































The purpose of this brief questionnaire is to obtain your feedback about the LEAP training and 
to identify areas where you would benefit from receiving additional information. We will have 
a brief discussion of your answers then ask that you turn in your completed test. 
 
Following the initial LEAP training session as well as your self-study review of the LEAP 
materials and Dr. Amador's book, "I Am Not Sick, I Don't Need Help;" Do you feel you would 
be comfortable employing LEAP principles with your clients? 
   
Circle one:        YES  NO 
 
Directions: Circle True or False for each statement listed below. All questions refer to your 
use of the LEAP approach with someone who has serious mental illness. Please do not refer to 
your copy of the book, slides or notes as this test is designed as a teaching tool.  
 
When faithfully following the LEAP approach, you should: 
 
 
T or F  1. Provide frequent and gentle reality testing. 
        
T or F  2. Ask questions and never make statements or give your opinion.   
 T or F  3. Not remind the person about bad treatment experiences if they  
have not brought them up, and instead focus only on the positives. 
 
T or F  4. Ask few questions as this can cause some consumers to feel  
threatened and paranoid.  
 
T or F  5. Never make statements or give your opinion unless invited to  
do so repeatedly.  
 
T or F  6. Not agree to help with, or partner on, goals that you think are  
unrealistic.   
 
T or F  7. Say things that make the person believe that you agree with his  
delusions (e.g., “I can see how the CIA has been harassing you. That 
must be very frustrating, yes?”) 
 
T or F 8. Gently and consistently point to the evidence that this person is 







T or F 9. Be sure to immediately clarify any misconceptions the person has 
about your opinion (e.g., if he thinks you believe his delusion or 
agree with him when he says, “I am not sick.”) 
 
T or F 10. Not ever allow the person to assume you agree with her when 
she says “I am not sick!” Instead, be sure to tell her your views on 
the matter to quickly correct her misunderstanding and ask that she 
agree to disagree with you. 
 
T or F  11. Never give your opinion about treatment. 
 
T or F 12. Focus your questions and listening on, among other things, what 
the person wants most no matter how bizarre or seemingly irrelevant 
it may seem (e.g., to have the alien transmitter taken out of his 
brain). 
 
T or F 13. After being asked your opinion on the matter, strongly 
encourage the person to take medicine telling her that you are 
absolutely certain it is indicated. 
 
T or F 14. When empathizing, try not to empathize with the person’s wish 
to avoid treatment. 
 
T or F 15. Allowing someone to mistakenly assume you agree with their 
delusion, without immediately correcting their mistake, is colluding 
with the delusion and will worsen it. 
 
T or F  16. Avoid reality testing. 
 
T or F 17. Reflect back what you have heard and ask the person whether or 
not you understood him correctly. 
 
T or F 18. Not have to apologize for your professional opinion (e.g., 
regarding the diagnosis, treatments indicated, etc.). 
 
T or F 19. Reflect back the perceived benefits of treatment, as the consumer 
describes them, even if they are incorrect (e.g., “the medication 
seems to improve my telepathy”).  
 
T or F 20. Never tell the person they need, or would benefit from,  
treatment. 
 
T or F 21. Focus, first and foremost, on helping the person develop insight 
into their illness. 
 







T or F 23. Feel comfortable having a friendly debate about whether the 
person should be in treatment or not. 
 
T or F  24. Never give a contrary opinion. 
 
 
Please answer the following questions in the space provided: 
 








2.  In the space below, reflect back the following statement: “These medications are 
making me hear voices and I need your help suing the hospital. You’ve got to help 








3. In the space below, reflect back the following statement: “My problem is you and 
everyone else that is telling me I am sick and have to take these medicines. I know 
what you’re up to repeating everything I say, I see how you’re working with my 
family to keep me locked up and poison me. They want me dead so they can sell 

















4. When asked for your opinion, which of the following are recommended delay 
tactics (circle all that apply): 
a. I don’t think it’s a good idea to tell you that right now. Okay? 
b. I would like to keep listening if that’s okay with you? 
c. Wouldn’t you agree that you’re opinion is far more important than mine? 
d. Can you tell me more first? 
e. Why do you want to know? 
f. I promise I will tell you what I think, but if it’s alright with you I would like 
to hear more about what we were talking about. Okay? 
g. That’s an interesting question, can you tell me more? 
h. Would you mind if we kept talking about_____ and I’ll tell you what I think 
later on? 
i. I am not allowed to answer that question just yet but I will get to it later. 
j. I will tell you what I think, but if it’s agreeable to you I would like to wait 
and hear some more because frankly, your opinion is far more important 
than mine anyway. 
 
5. You have been asked to give your opinion about whether treatment would be 
helpful or not. You have delayed as long as you can. The person asking believes 
that medicine will make him unable to work. In the space below describe what you 










6. In the space below, please feel free to ask any questions you may have regarding 



















APPENDIX D: LEAP Fidelity Measure 
 
LEAP FIDELITY MEASURE 
 Clinician ID:      Date:      
Please think about clinical encounters you have had over the past six weeks with a client 
diagnosed with Schizophrenia and who has demonstrated a lack of insight into their 
diagnosis.  Rate how often you have used the following techniques on a scale of 1 
(Never), 3 (Sometimes), and 5 (Always). You can use any rating between 1 through 5. 
       
 
LEAP Intervention Always  Often  Sometimes  Rarely  Never   
1 
Listened to the client’s 
frustrations, fears and 
desires. 
5 4 3 2 1   
2 
Listened to client’s 
discussions of delusions or 
hallucinations without 
reacting, omitting, or reality 
testing. 
5 4 3 2 1   




Requested feedback from 
client regarding accuracy of 
my reflected statements. 
5 4 3 2 1   
5 
Made attempts to delay 
giving opinions that are 
contrary to the client’s. 
5 4 3 2 1 
6 
Preceded contrary opinions 
with an Apology, 
Acknowledging my 
Fallibility, or Agreeing to 
Disagree (3 A’s). 
5 4 3 2 1 
7 Only gave contrary opinions with the client's permission. 5 4 3 2 1 
8 Did not offer contrary opinions unless necessary. 5 4 3 2 1 
9 Apologized for opinions that differ from the client's. 5 4 3 2 1 
10 
Empathized with client's 
frustrations, fears and 
desires. 
5 4 3 2 1 
11 
Empathized with the client's 
feelings about their 
illness/diagnosis. 









12 Empathized with the client's feelings about treatment. 5 4 3 2 1 
13 Normalized the client's feelings. 5 4 3 2 1 
14 
Actively identified goals that 
both my client and I agree 
on. 
5 4 3 2 1 
15 Articulated shared goals with client. 5 4 3 2 1 
16 Developed a plan to achieve shared goals with the client. 5 4 3 2 1 
17 
Engaged the client in an 
ongoing assessment of 
progress made toward the 
shared goals. 
5 4 3 2 1 
